Document_and_Entity_Informatio
Document and Entity Information (USD $) | 12 Months Ended | ||
Sep. 30, 2013 | Dec. 24, 2013 | Mar. 29, 2013 | |
Document Type | '10-K | ' | ' |
Amendment Flag | 'false | ' | ' |
Document Period End Date | 30-Sep-13 | ' | ' |
Trading Symbol | 'avxl | ' | ' |
Entity Registrant Name | 'ANAVEX LIFE SCIENCES CORP. | ' | ' |
Entity Central Index Key | '0001314052 | ' | ' |
Current Fiscal Year End Date | '--09-30 | ' | ' |
Entity Filer Category | 'Smaller Reporting Company | ' | ' |
Entity Common Stock, Shares Outstanding | ' | 37,237,588 | ' |
Entity Current Reporting Status | 'Yes | ' | ' |
Entity Voluntary Filers | 'No | ' | ' |
Entity Well Known Seasoned Issuer | 'No | ' | ' |
Entity Public Float | ' | ' | $16,460,398 |
Document Fiscal Year Focus | '2013 | ' | ' |
Document Fiscal Period Focus | 'FY | ' | ' |
CONSOLIDATED_BALANCE_SHEETS
CONSOLIDATED BALANCE SHEETS (USD $) | Sep. 30, 2013 | Sep. 30, 2012 |
Current | ' | ' |
Cash | $345,074 | $11,362 |
Prepaid expenses | 48,375 | 0 |
Deferred financing charge | 0 | 1,215 |
Total Current Assets | 393,449 | 12,577 |
Equipment | 0 | 576 |
Total Assets | 393,449 | 13,153 |
Current | ' | ' |
Accounts payable and accrued liabilities | 1,741,797 | 2,589,324 |
Promissory notes payable | 210,863 | 299,000 |
Total Current Liabilities | 1,952,660 | 2,888,324 |
Derivative liability | 904,000 | 0 |
Total Liabilities | 2,856,660 | 2,888,324 |
CAPITAL DEFICIT | ' | ' |
Capital stock Authorized: 150,000,000 common shares, par value $0.001 per share Issued and outstanding: 37,237,588 common shares (September 30, 2012 - 30,240,687) | 37,238 | 30,241 |
Additional paid-in capital | 38,644,523 | 34,599,514 |
Share subscriptions received | 60,000 | 0 |
Deficit accumulated during the development stage | -41,204,972 | -37,504,926 |
Total Stockholder's Equity | -2,463,211 | -2,875,171 |
Total Liabilities and Stockholder's Equity | $393,449 | $13,153 |
CONSOLIDATED_BALANCE_SHEETS_Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $) | Sep. 30, 2013 | Sep. 30, 2012 |
Common Stock, Shares Authorized | 150,000,000 | 150,000,000 |
Common Stock, Par Value Per Share | $0.00 | $0.00 |
Common Stock, Shares, Issued | 37,237,588 | 30,240,687 |
Common Stock, Shares, Outstanding | 37,237,588 | 30,240,687 |
CONSOLIDATED_STATEMENTS_OF_OPE
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) | 12 Months Ended | 116 Months Ended | |
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | |
Expenses | ' | ' | ' |
Accounting and audit fees | $136,758 | $139,761 | $798,872 |
Amortization and depreciation | 576 | 1,858 | 5,631 |
Bank charges and interest | 4,397 | 5,963 | 46,704 |
Consulting fees | 271,898 | 1,155,366 | 12,015,989 |
Insurance | 16,125 | 10,844 | 75,121 |
Investor relations | 128,575 | 108,138 | 960,282 |
Legal fees | 176,318 | 142,923 | 846,343 |
Management fees | 0 | 0 | 14,625 |
Office and miscellaneous expense | 4,019 | 9,147 | 151,703 |
Registration and filing fees | 33,634 | 26,794 | 188,032 |
Rent and administration | 12,000 | 0 | 236,670 |
Research and development | 263,847 | 2,653,860 | 12,822,796 |
Salaries and wages | 1,067,294 | 0 | 1,067,294 |
Travel | 19,695 | 66,837 | 760,850 |
Website design and maintenance | 2,231 | 0 | 30,648 |
Loss before other income (expenses) | -2,137,367 | -4,321,491 | -30,021,560 |
Other income (expenses) | ' | ' | ' |
Interest and financing fees | -51,341 | -138,341 | -677,362 |
Accretion of debt discount | 0 | -98,081 | -2,174,661 |
Change in fair value of derivative liability | 15,000 | 67,500 | -448,274 |
Debt conversion expense | 0 | 0 | -504,160 |
Loss on settlement of accounts payable | -976,880 | 0 | -1,754,933 |
Loss on extinguishment of debt | -495,328 | -3,829,333 | -5,010,868 |
Foreign exchange gain (loss) | -54,130 | 18,041 | -62,350 |
Net loss for the period | ($3,700,046) | ($8,301,705) | ($40,654,168) |
Basic and diluted loss per share | ($0.12) | ($0.29) | ' |
Weighted average number of shares outstanding | 31,908,441 | 28,168,784 | ' |
CONSOLIDATED_STATEMENTS_OF_CAS
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) | 12 Months Ended | 116 Months Ended | |
Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | |
Cash Flows used in Operating Activities | ' | ' | ' |
Net loss for the period | ($3,700,046) | ($8,301,705) | ($40,654,168) |
Adjustments to reconcile net loss to net cash used in operations: | ' | ' | ' |
Amortization and depreciation | 576 | 1,858 | 5,631 |
Accretion of debt discount | 0 | 98,081 | 2,174,661 |
Stock-based compensation | 1,002,500 | 302,208 | 5,845,047 |
Amortization of deferred financing charge | 1,215 | 62,399 | 163,927 |
Change in fair value of derivative liability | -15,000 | -67,500 | 448,274 |
Consulting expense recorded in exchange for shares to be issued | 0 | 0 | 236,337 |
Common shares issued for consulting expenses | 0 | 15,895 | 406,405 |
Promissory note issued for severance | 0 | 0 | 71,500 |
Common shares issued for severance | 0 | 75,000 | 415,600 |
Common shares issued for research and development expenses | 0 | 0 | 800,000 |
Management fees contributed | 0 | 0 | 14,625 |
Debt conversion expense | 0 | 0 | 504,160 |
Loss on settlement of accounts payable | 976,880 | 0 | 1,754,933 |
Loss on extinguishment of debt | 495,328 | 3,829,333 | 5,010,868 |
Rent contributed | 0 | 0 | 3,750 |
Unrealized foreign exchange | -4,937 | 0 | -4,937 |
Changes in non-cash working capital balances related to operations: | ' | ' | ' |
VAT recoverable | 0 | 809 | 0 |
Prepaid expenses | 0 | 9,630 | 0 |
Accounts payable and accrued liabilities | 465,911 | 2,281,052 | 6,238,459 |
Net cash used in operating activities | -777,573 | -1,692,940 | -16,564,928 |
Cash Flows used in Investing Activities | ' | ' | ' |
Acquisition of equipment | 0 | 0 | -5,631 |
Net cash used in investing activities | 0 | 0 | -5,631 |
Cash Flows provided by Financing Activities | ' | ' | ' |
Issuance of common shares, net of share issue costs | 801,285 | 996,250 | 11,048,118 |
Share subscriptions received | 60,000 | 0 | 60,000 |
Proceeds from promissory notes | 250,000 | 581,500 | 5,649,000 |
Financing fees | 0 | -8,150 | -108,150 |
Repayment of promissory note | 0 | 0 | -100,000 |
Due to related parties | 0 | 0 | 33,665 |
Shareholder advances | 0 | 0 | 333,000 |
Net cash provided by financing activities | 1,111,285 | 1,569,600 | 16,915,633 |
Increase (decrease) in cash during the period | 333,712 | -123,340 | 345,074 |
Cash, beginning of period | 11,362 | 134,702 | 0 |
Cash, end of period | $345,074 | $11,362 | $345,074 |
Consolidated_Statement_of_Chan
Consolidated Statement of Changes in Capital Deficit (USD $) | Common Stock [Member] | Common Stock Additional Paid-In Capital [Member] | Common Shares to be Issued [Member] | Deficit Accumulated During the Development Stage [Member] | Total |
Beginning Balance at Jan. 22, 2004 | ' | ' | ' | ' | ' |
Capital stock issued for cash on January 23, 2004 - at $0.0033 | $12,000 | $28,000 | ' | ' | $40,000 |
Capital stock issued for cash on January 23, 2004 - at $0.0033 (Shares) | 12,000,000 | ' | ' | ' | ' |
Net Income (Loss) | ' | ' | ' | -14,395 | -14,395 |
Ending Balance at Sep. 30, 2004 | 12,000 | 28,000 | ' | -14,395 | 25,605 |
Ending Balance (Shares) at Sep. 30, 2004 | 12,000,000 | ' | ' | ' | ' |
Capital stock issued for cash on December 31, 2004 - at $0.0033 | 7,200 | 16,800 | ' | ' | 24,000 |
Capital stock issued for cash on December 31, 2004 - at $0.0033 (Shares) | 7,200,000 | ' | ' | ' | ' |
Management fees contributed | ' | 13,000 | ' | ' | 13,000 |
Rent contributed | ' | 3,000 | ' | ' | 3,000 |
Net Income (Loss) | ' | ' | ' | -91,625 | -91,625 |
Ending Balance at Sep. 30, 2005 | 19,200 | 60,800 | ' | -106,020 | -26,020 |
Ending Balance (Shares) at Sep. 30, 2005 | 19,200,000 | ' | ' | ' | ' |
Management fees contributed | ' | 1,625 | ' | ' | 1,625 |
Rent contributed | ' | 750 | ' | ' | 750 |
Debt forgiven by directors | ' | 33,666 | ' | ' | 33,666 |
Net Income (Loss) | ' | ' | ' | -25,532 | -25,532 |
Ending Balance at Sep. 30, 2006 | 19,200 | 96,841 | ' | -131,552 | -15,511 |
Beginning Balance (Shares) at Sep. 30, 2006 | 19,200,000 | ' | ' | ' | ' |
Capital stock issued for research and development services on September 24, 2007 - at $3.60 | 222 | 799,778 | ' | ' | 800,000 |
Capital stock issued for research and development services on September 24, 2007 - at $3.60 (Shares) | 222,222 | ' | ' | ' | ' |
Capital stock issued for settlement of loan payable on September 25, 2007 - at $3.60 | 93 | 332,907 | ' | ' | 333,000 |
Capital stock issued for settlement of loan payable on September 25, 2007 - at $3.60 (Shares) | 92,500 | ' | ' | ' | ' |
Net Income (Loss) | ' | ' | ' | -1,579,993 | -1,579,993 |
Ending Balance at Sep. 30, 2007 | 19,515 | 1,229,526 | ' | -1,711,545 | -462,504 |
Ending Balance (Shares) at Sep. 30, 2007 | 19,514,722 | ' | ' | ' | ' |
Capital stock issued for cash on December 10, 2007- at $3.50 | 150 | 524,850 | ' | ' | 525,000 |
Capital stock issued for cash on December 10, 2007- at $3.50 (Shares) | 150,000 | ' | ' | ' | ' |
Capital stock issued for consulting services on December 18, 2007 - at $3.86 | 50 | 192,950 | ' | ' | 193,000 |
Capital stock issued for consulting services on December 18, 2007 - at $3.86 (Shares) | 50,000 | ' | ' | ' | ' |
Capital stock issued debt settlement of debt on December 18, 2007- at $4.50 | 10 | 44,990 | ' | ' | 45,000 |
Capital stock issued debt settlement of debt on December 18, 2007- at $4.50 (Shares) | 10,000 | ' | ' | ' | ' |
Stock-based compensation for shares issued at a discount | ' | 65,000 | ' | ' | 65,000 |
Capital stock issued for severance on May 15, 2008 - at $5.24 | 65 | 340,535 | ' | ' | 340,600 |
Capital stock issued for severance on May 15, 2008 - at $5.24 (Share) | 65,000 | ' | ' | ' | ' |
Common stock to be issued for consulting services | ' | ' | 252,599 | ' | 252,599 |
Capital stock issued for consulting services on August 19, 2008 - at $5.07 | 25 | 126,725 | -126,750 | ' | ' |
Capital stock issued for consulting services on August 19, 2008 - at $5.07 (Shares) | 25,000 | ' | ' | ' | ' |
Capital stock issued for cash on August 19,2008 - at $4.25 | 142 | 606,325 | ' | ' | 606,467 |
Capital stock issued for cash on August 19,2008 - at $4.25 (Shares) | 142,698 | ' | ' | ' | ' |
Stock based compensation | ' | 1,493,937 | ' | ' | 1,493,937 |
Net Income (Loss) | ' | ' | ' | -5,351,269 | -5,351,269 |
Ending Balance at Sep. 30, 2008 | 19,957 | 4,624,838 | 125,849 | -7,062,814 | -2,292,170 |
Ending Balance (Shares) at Sep. 30, 2008 | 19,957,420 | ' | ' | ' | ' |
Capital stock issued for consulting services on November 20, 2008 at $2.63 | 25 | 65,725 | -65,750 | ' | ' |
Capital stock issued for consulting services on November 20, 2008 at $2.63 (Shares) | 25,000 | ' | ' | ' | ' |
Capital stock issued for consulting services on February 20, 2009 at $2.50 | 25 | 62,475 | -62,500 | ' | ' |
Capital stock issued for consulting services on February 20, 2009 at $2.50 (Shares) | 25,000 | ' | ' | ' | ' |
Capital stock issued for cash on March 6, 2009 at $2.25 | 89 | 200,494 | ' | ' | 200,583 |
Capital stock issued for cash on March 6, 2009 at $2.25 (Shares) | 89,148 | ' | ' | ' | ' |
Capital stock issued for consulting services on March 20, 2009 at $2.00 | 3 | 4,997 | ' | ' | 5,000 |
Capital stock issued for consulting services on March 20, 2009 at $2.00 (Shares) | 2,500 | ' | ' | ' | ' |
Capital stock issued for cash on March 20, 2009 at $2.25 | 11 | 24,289 | ' | ' | 24,300 |
Capital stock issued for cash on March 20, 2009 at $2.25 (Shares) | 10,800 | ' | ' | ' | ' |
Capital stock issued for cash on June 11, 2009 at $2.25 | 36 | 80,964 | ' | ' | 81,000 |
Capital stock issued for cash on June 11, 2009 at $2.25 (Shares) | 36,000 | ' | ' | ' | ' |
Capital stock issued for services on June 11, 2009 at $2.25 | 29 | 65,731 | ' | ' | 65,760 |
Capital stock issued for services on June 11, 2009 at $2.25 (Shares) | 29,227 | ' | ' | ' | ' |
Capital stock issued for cash on June 19, 2009 at $2.25 | 496 | 1,114,504 | ' | ' | 1,115,000 |
Capital stock issued for cash on June 19, 2009 at $2.25 (Shares) | 495,556 | ' | ' | ' | ' |
Capital stock issued for finders fees on June 26, 2009 at $2.51 | 22 | 55,755 | ' | ' | 55,777 |
Capital stock issued for finders fees on June 26, 2009 at $2.51 (Shares) | 22,222 | ' | ' | ' | ' |
Shares to be issued for consulting services | ' | ' | 236,337 | ' | 236,337 |
Capital stock issued for cash on August 19, 2009 at $2.25 | 129 | 289,869 | ' | ' | 289,998 |
Capital stock issued for cash on August 19, 2009 at $2.25 (Shares) | 128,888 | ' | ' | ' | ' |
Less: Finders fees | ' | -72,850 | ' | ' | -72,850 |
Beneficial conversion features on convertible debt issuances | ' | 333,056 | ' | ' | 333,056 |
Extinguishment of debt | ' | 487,469 | ' | ' | 487,469 |
Cancellation of common shares | -75 | 234,011 | -233,936 | ' | ' |
Cancellation of common shares (Shares) | -75,000 | ' | ' | ' | ' |
Share subscriptions received | ' | ' | 300,000 | ' | 300,000 |
Stock based compensation | ' | 812,336 | ' | ' | 812,336 |
Net Income (Loss) | ' | ' | ' | -5,499,419 | -5,499,419 |
Ending Balance at Sep. 30, 2009 | 20,747 | 8,383,663 | 300,000 | -12,562,233 | -3,857,823 |
Ending Balance (Shares) at Sep. 30, 2009 | 20,746,761 | ' | ' | ' | ' |
Cumulative effect of accounting changes | ' | -333,056 | ' | -550,804 | -883,860 |
Capital stock issued for cash on October 2, 2009 at $2.25 | 267 | 599,733 | -300,000 | ' | 300,000 |
Capital stock issued for cash on October 2, 2009 at $2.25 (Shares) | 266,666 | ' | ' | ' | ' |
Capital stock issued in settlement of promissory note on February 2, 2010 at $2.02 | 49 | 99,951 | ' | ' | 100,000 |
Capital stock issued in settlement of promissory note on February 2, 2010 at $2.02 (Shares) | 49,505 | ' | ' | ' | ' |
Capital stock issued for cash on April 9, 2010 - at $2.60 | 93 | 240,405 | ' | ' | 240,498 |
Capital stock issued for cash on April 9, 2010 - at $2.60 (Shares) | 92,499 | ' | ' | ' | ' |
Capital stock issued in settlement of debt on April 30, 2010 - at $2.85 | 9 | 27,991 | ' | ' | 28,000 |
Capital stock issued in settlement of debt on April 30, 2010 - at $2.85 (Shares) | 9,825 | ' | ' | ' | ' |
Finders' fees paid in cash | ' | -24,050 | ' | ' | -24,050 |
Capital stock issued for cash on June 29, 2010 - at $2.50 | 941 | 2,351,559 | ' | ' | 2,352,500 |
Capital stock issued for cash on June 29, 2010 - at $2.50 (Shares) | 941,000 | ' | ' | ' | ' |
Finders fees paid in cash 2 | ' | -206,500 | ' | ' | -206,500 |
Capital stock issued in settlement of debt on July 5, 2010 at $2.50 | 400 | 999,600 | ' | ' | 1,000,000 |
Capital stock issued in settlement of debt on July 5, 2010 at $2.50 (Shares) | 400,000 | ' | ' | ' | ' |
Capital stock issued for cash on September 3, 2010 at $2.75 | 163 | 448,087 | ' | ' | 448,250 |
Capital stock issued for cash on September 3, 2010 at $2.75 (Shares) | 163,000 | ' | ' | ' | ' |
Capital stock issued for finders fees on September 3, 2010 at $2.75 | 9 | -9 | ' | ' | ' |
Capital stock issued for finders fees on September 3, 2010 at $2.75 (Shares) | 9,000 | ' | ' | ' | ' |
Finders' fees paid in cash 3 | ' | -15,125 | ' | ' | -15,125 |
Shares issued on conversion of promissory note on September 30, 2010 at $2.25 | 328 | 737,802 | ' | ' | 738,130 |
Shares issued on conversion of promissory note on September 30, 2010 at $2.25 (Shares) | 328,058 | ' | ' | ' | ' |
Shares issued on conversion of promissory note on September 30, 2010 at $2.35 | 511 | 1,199,489 | ' | ' | 1,200,000 |
Shares issued on conversion of promissory note on September 30, 2010 at $2.35 (Shares) | 510,638 | ' | ' | ' | ' |
Reclassification of derivative liability on modification of note | ' | 3,144,520 | ' | ' | 3,144,520 |
Settlement of accounts payable | ' | 444,000 | ' | ' | 444,000 |
Equity component of convertible promissory note | ' | 44,220 | ' | ' | 44,220 |
Stock based compensation | ' | 770,055 | ' | ' | 770,055 |
Net Income (Loss) | ' | ' | ' | -8,783,037 | -8,783,037 |
Ending Balance at Sep. 30, 2010 | 23,517 | 18,912,335 | ' | -21,896,074 | -2,960,222 |
Ending Balance (Shares) at Sep. 30, 2010 | 23,516,952 | ' | ' | ' | ' |
Capital stock issued for cash on November 18, 2010 at $2.75 | 393 | 1,082,682 | ' | ' | 1,083,075 |
Capital stock issued for cash on November 18, 2010 at $2.75 (Shares) | 393,846 | ' | ' | ' | ' |
Less: Share issue costs | ' | -65,363 | ' | ' | -65,363 |
Capital stock issued for finders fees on November 18, 2010 at $2.75 | 4 | -4 | ' | ' | ' |
Capital stock issued for finders fees on November 18, 2010 at $2.75 (Shares) | 3,636 | ' | ' | ' | ' |
Shares issued on conversion of promissory note on November 18, 2010 at $2.25 | 853 | 1,918,565 | ' | ' | 1,919,418 |
Shares issued on conversion of promissory note on November 18, 2010 at $2.25 (Shares) | 853,075 | ' | ' | ' | ' |
Debt conversion expense | ' | 504,160 | ' | ' | 504,160 |
Shares issued on the conversion of a promissory note on November 18, 2010 - at $4.12 | 145 | 597,515 | ' | ' | 597,660 |
Shares issued on the conversion of a promissory note on November 18, 2010 - at $4.12 (Shares) | 145,063 | ' | ' | ' | ' |
Capital stock issued in settlement of debt on November 18, 2010 - at $4.12 | 182 | 748,908 | ' | ' | 749,090 |
Capital stock issued in settlement of debt on November 18, 2010 - at $4.12 (Shares) | 181,818 | ' | ' | ' | ' |
Capital stock issued for cash on November 25, 2010 at $3.35 | 30 | 99,970 | ' | ' | 100,000 |
Capital stock issued for cash on November 25, 2010 at $3.35 (Shares) | 29,851 | ' | ' | ' | ' |
Capital stock issued for finders fees on November 25, 2010 at $3.35 | 3 | -3 | ' | ' | ' |
Capital stock issued for finders fees on November 25, 2010 at $3.35 (Shares) | 2,985 | ' | ' | ' | ' |
Capital stock issued for cash on February 1, 2011 - at $3.75 | 61 | 228,739 | ' | ' | 228,800 |
Capital stock issued for cash on February 1, 2011 - at $3.75 (Shares) | 61,014 | ' | ' | ' | ' |
Capital stock issued for cash on May 3, 2011 - at $3.00 | 34 | 99,966 | ' | ' | 100,000 |
Capital stock issued for cash on May 3, 2011 - at $3.00 (Shares) | 33,334 | ' | ' | ' | ' |
Capital stock issued on exercise of warrants for cash on June 19, 2011 - at $2.25 | 700 | 1,574,300 | ' | ' | 1,575,000 |
Capital stock issued on exercise of warrants for cash on June 19, 2011 - at $2.25 (Shares) | 700,000 | ' | ' | ' | ' |
Equity units issued in settlement of an account payable on September 28, 2011 | 650 | 1,059,313 | ' | ' | 1,059,963 |
Equity units issued in settlement of an account payable on September 28, 2011 (Shares) | 650,000 | ' | ' | ' | ' |
Stock based compensation | ' | 1,273,162 | ' | ' | 1,273,162 |
Net Income (Loss) | ' | ' | ' | -7,307,147 | -7,307,147 |
Ending Balance at Sep. 30, 2011 | 26,572 | 28,034,245 | ' | -29,203,221 | -1,142,404 |
Ending Balance (Shares) at Sep. 30, 2011 | 26,571,574 | ' | ' | ' | ' |
Rent contributed | ' | ' | ' | ' | 0 |
Capital stock issued for cash on December 6, 2011 - at $1.25 | 616 | 768,884 | ' | ' | 769,500 |
Capital stock issued for cash on December 6, 2011 - at $1.25 (Shares) | 615,600 | ' | ' | ' | ' |
Less: Share issue costs | ' | -77,000 | ' | ' | -77,000 |
Capital stock issued for cash on February 9, 2012 - at $1.25 | 270 | 337,230 | ' | ' | 337,500 |
Capital stock issued for cash on February 9, 2012 - at $1.25 Shares | 270,000 | ' | ' | ' | ' |
Less: Share Issue costs 2 | ' | -33,750 | ' | ' | -33,750 |
Equity units issued for services on February 9, 2012 - at $1.99 | 8 | 15,888 | ' | ' | 15,896 |
Equity units issued for services on February 9, 2012 - at $1.99 (Share) | 8,000 | ' | ' | ' | ' |
Equity units issued for settlement of loans payable on May 31, 2012 | 2,700 | 5,176,884 | ' | ' | 5,179,584 |
Equity units issued for settlement of loans payable on May 31, 2012 (Share) | 2,700,513 | ' | ' | ' | ' |
Capital stock issued for services on July 12, 2012 - at $1.00 | 75 | 74,925 | ' | ' | 75,000 |
Capital stock issued for services on July 12, 2012 - at $1.00 (Shares) | 75,000 | ' | ' | ' | ' |
Stock based compensation | ' | 302,208 | ' | ' | 302,208 |
Net Income (Loss) | ' | ' | ' | -8,301,705 | -8,301,705 |
Ending Balance at Sep. 30, 2012 | 30,241 | 34,599,514 | ' | -37,504,926 | -2,875,171 |
Ending Balance (Shares) at Sep. 30, 2012 | 30,240,687 | ' | ' | ' | ' |
Rent contributed | ' | ' | ' | ' | 0 |
Equity units issued for settlement of loans payable on July 5, 2013 | 4,209 | 2,563,011 | ' | ' | 2,567,220 |
Equity units issued for settlement of loans payable on July 5, 2013 (Shares) | 4,208,910 | ' | ' | ' | ' |
Capital stock issued for cash on July 5, 2013 - at $0.40 | 2,196 | 563,257 | ' | ' | 565,453 |
Capital stock issued for cash on July 5, 2013 - at $0.40 (Shares) | 2,196,133 | ' | ' | ' | ' |
Less: Share issue costs | ' | -112,174 | ' | ' | -112,174 |
Initial purchase shares issued under equity line on July 5, 2013 - at $0.40 | 592 | 99,750 | ' | ' | 100,342 |
Initial purchase shares issued under equity line on July 5, 2013 - at $0.40 (Shares) | 591,858 | ' | ' | ' | ' |
Less: Share Issue costs 2 | ' | -71,335 | ' | ' | -71,335 |
Common stock to be issued for cash - at $0.50 | ' | ' | 60,000 | ' | 60,000 |
Stock based compensation | ' | 1,002,500 | ' | ' | 1,002,500 |
Net Income (Loss) | ' | ' | ' | -3,700,046 | -3,700,046 |
Ending Balance at Sep. 30, 2013 | $37,238 | $38,644,523 | $60,000 | ($41,204,972) | ($2,463,211) |
Ending Balance (Shares) at Sep. 30, 2013 | 37,237,588 | ' | ' | ' | ' |
Business_Description_Basis_of_
Business Description, Basis of Presentation and Liquidity | 12 Months Ended | |
Sep. 30, 2013 | ||
Business Description, Basis of Presentation and Liquidity [Text Block] | ' | |
Note 1 | Business Description, Basis of Presentation and Liquidity | |
Business | ||
Anavex Life Sciences Corp. (the “Company”) is a pharmaceutical company engaged in the development of drug candidates. | ||
The Company’s lead compound, ANAVEX 2-73 is being developed to treat Alzheimer’s disease through disease modification. | ||
In pre-clinical studies conducted in France, and in Greece, ANAVEX 2-73 demonstrated anti- amnesic and neuroprotective properties. Based on these pre-clinical studies, the Company sponsored a Phase 1 single ascending dose study of ANAVEX 2-73, which was initiated and completed in 2011. This study was conducted in Germany in collaboration with ABX-CRO Advanced Pharmaceutical Services. The study indicated that ANAVEX 2-73 was well tolerated by study subjects in doses up to 55mg. During the year ended September 30, 2013, clinical trials had been delayed due to lack of funding. On July 5, 2013, the Company completed the closing of a private placement offering and a $10,000,000 purchase agreement (Note 7), the proceeds from which the Company will use to further its business plan and clinical trials of ANAVEX 2-73. | ||
The Company plans to initiate a multiple ascending dose study of ANAVEX 2-73 in the first half of fiscal year 2014. Additionally we intend to identify and initiate discussions with potential partners in the next 12 months. Further, we may acquire or develop new intellectual property and assign, license, or otherwise transfer our intellectual property to further our goals. | ||
Basis of Presentation and Liquidity | ||
These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the instructions to Form 10-K. | ||
These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America on a going concern basis, which assumes that the Company will continue to realize its assets and discharge its obligations and commitments in the normal course of operations. Realization values may be substantially different from carrying values as shown, and these financial statements do not give effect to adjustments that would be necessary to the carrying values and classification of assets and liabilities should the Company be unable to continue as a going concern. At September 30, 2013, the Company had an accumulated deficit of $41,204,972 (2012 - $37,504,926), had a working capital deficit of $1,559,212 and expects to incur further losses in the development of its business, all of which casts substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to generate future profitable operations and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management has no formal plan in place to address this but considers obtaining additional funds by equity financing and/or from issuing promissory notes. Management expects the Company’s cash requirement over the next twelve months to be approximately $6,000,000. While the Company is expending its best efforts to achieve the above plans, there is no assurance that any such activity will generate funds for operations. |
Summary_of_Significant_Account
Summary of Significant Accounting Policies | 12 Months Ended | |||
Sep. 30, 2013 | ||||
Summary of Significant Accounting Policies [Text Block] | ' | |||
Note 2 | Summary of Significant Accounting Policies | |||
a) | Use of Estimates | |||
The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to deferred income tax asset valuations, asset impairment, conversion features embedded in convertible notes payable, derivative valuations, stock based compensation and loss contingencies. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. | ||||
b) | Principles of Consolidation | |||
These consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiary, Anavex Life Sciences (France) SA, a company incorporated under the laws of France. All inter-company transactions and balances have been eliminated. | ||||
c) | Development Stage Company | |||
The Company is devoting substantially all of its present efforts to establish a new business and none of its planned principal operations have commenced. All losses accumulated since inception have been considered as part of the Company’s development stage activities. | ||||
d) | Equipment | |||
Equipment is recorded at cost and is depreciated at 33% per annum on the straight-line basis. | ||||
e) | Impairment of Long-Lived Assets | |||
The Company reviews the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The estimated future cash flows are based upon, among other things, assumptions about future operating performance, and may differ from actual cash flows. Long-lived assets evaluated for impairment are grouped with other assets to the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. If the sum of the projected undiscounted cash flows (excluding interest) is less than the carrying value of the assets, the assets will be written down to the estimated fair value in the period in which the determination is made. | ||||
f) | Financial Instruments | |||
The carrying value of the Company’s financial instruments, consisting of cash and accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of such instruments. Based on borrowing rates currently available to the Company for similar terms and based on the short term duration of the debt instruments, the carrying value of the promissory notes payable approximate their fair value. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments. | ||||
g) | Foreign Currency Translation | |||
The functional currency of the Company is the US dollar. Monetary items denominated in a foreign currency are translated into US dollars at exchange rates prevailing at the balance sheet date and non-monetary items are translated at exchange rates prevailing when the assets were acquired or obligations incurred. Foreign currency denominated expense items are translated at exchange rates prevailing at the transaction date. Unrealized gains or losses arising from the translations are credited or charged to income in the period in which they occur. | ||||
h) | Research and Development Expenses | |||
Research and developments costs are expensed as incurred. These expenses are comprised of the costs of the Company’s proprietary research and development efforts, including salaries, facilities costs, overhead costs and other related expenses as well as costs incurred in connection with third-party collaboration efforts. Milestone payments made by the Company to third parties are expensed when the specific milestone has been achieved. | ||||
In addition, the Company incurs expenses in respect of the acquisition of intellectual property relating to patents. The probability of success and length of time to developing commercial applications of the drugs subject to the acquired patents and trademarks is difficult to determine and numerous risks and uncertainties exist with respect to the timely completion of the development projects. There is no assurance the acquired patents will ever be successfully commercialized. Due to these risks and uncertainties, the acquisition costs of patents do not meet the definition of an asset and thus are expensed as incurred. | ||||
i) | Income Taxes | |||
The Company has adopted the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. | ||||
The Company has adopted the provisions of FASB ASC 740 "Income Taxes" regarding accounting for uncertainty in income taxes. The Company initially recognizes tax positions in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority, assuming full knowledge of the position and all relevant facts. Application requires numerous estimates based on available information. The Company considers many factors when evaluating and estimating its tax positions and tax benefits, and its recognized tax positions and tax benefits may not accurately anticipate actual outcomes. As additional information is obtained, there may be a need to periodically adjust the recognized tax positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements of operations. | ||||
j) | Basic and Diluted Loss per Share | |||
The basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding. Diluted loss per common share is computed similar to basic loss per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. For the year ended September 30, 2013, loss per share excludes 12,224,479 (2012 – 6,025,141) potentially dilutive common shares (related to outstanding options and warrants) as their effect was anti-dilutive. | ||||
k) | Stock-based Compensation | |||
The Company accounts for all stock-based payments and awards under the fair value based method. | ||||
Stock-based payments to non-employees are measured at the fair value of the consideration received, or the fair value of the equity instruments issued, or liabilities incurred, whichever is more reliably measurable. The fair value of stock-based payments to non-employees is periodically re-measured until the counterparty performance is complete, and any change therein is recognized over the vesting period of the award and in the same manner as if the Company had paid cash instead of paying with or using equity based instruments. Compensation costs for stock-based payments with graded vesting are recognized on a straight-line basis. The cost of the stock-based payments to non- employees that are fully vested and non-forfeitable as at the grant date is measured and recognized at that date, unless there is a contractual term for services in which case such compensation would be amortized over the contractual term. | ||||
The Company accounts for the granting of share purchase options to employees using the fair value method whereby all awards to employees will be recorded at fair value on the date of the grant. The fair value of all share purchase options are expensed over their vesting period with a corresponding increase to additional paid-in capital. | ||||
The Company uses the Black-Scholes option valuation model to calculate the fair value of share purchase options at the date of the grant. Option pricing models require the input of highly subjective assumptions, including the expected price volatility. Changes in these assumptions can materially affect the fair value estimates. | ||||
l) | Fair Value Measurements | |||
The fair value hierarchy under GAAP is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following: | ||||
Level 1 - | quoted prices (unadjusted) in active markets for identical assets or liabilities; | |||
Level 2 - | observable inputs other than Level I, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and | |||
Level 3 - | assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities. | |||
The book value of cash and accounts payable and accrued liabilities approximate their fair values due to the short term maturity of those instruments. Based on borrowing rates currently available to the Company under similar terms, the book value of promissory notes payable approximates their fair values. The Company’s promissory notes payable are based on Level 2 inputs in the ASC 820 fair value hierarchy. | ||||
At September 30, 2013, the Company’s Level 3 liabilities consisted of share purchase warrants that are required to be accounted for as liabilities pursuant to ASC 815 because the terms of the warrants contain provisions that are in violation of the fixed for fixed criteria of that guidance. | ||||
The Company calculated the fair value at the inception of these contracts and as at September 30, 2013 using the binomial option pricing model to determine the fair value, using the following assumptions: | ||||
At September | ||||
At inception | 30, 2013 | |||
Risk-free interest rate | 0.28% | 0.10% | ||
Expected life (years) | 1.49 | 1.25 | ||
Expected volatility | 81.57% | 77.51% | ||
Stock price | $0.61 | $0.65 | ||
Dividend yields | 0.00% | 0.00% | ||
Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances (for example, when there is evidence of impairment). There were no assets or liabilities measured at fair value on a nonrecurring basis during the periods ended September 30, 2013 and 2012. | ||||
m) | Derivative Liabilities | |||
The Company evaluates its financial instruments and other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815 Derivatives and Hedging. The result of this accounting treatment is that the fair value of the embedded derivative is marked- to-market at each balance sheet date and recorded as a liability and the change in fair value is recorded in the consolidated statements of operations as other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. | ||||
The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instruments that become subject to reclassification are reclassified at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not settlement of the derivative instrument is expected within 12 months of the balance sheet date. | ||||
The Company uses the binomial option pricing model to value derivative liabilities. This model uses Level 3 inputs in the fair value hierarchy established by ASC 820 Fair Value Measurement. | ||||
n) | Recent Accounting Pronouncements | |||
There are no new accounting pronouncements that the Company recently adopted or are pending the Company’s adoption that are expected to have a material impact on the company’s results of operations, financial position or cash flows. |
Equipment
Equipment | 12 Months Ended | ||||||||||
Sep. 30, 2013 | |||||||||||
Equipment [Text Block] | ' | ||||||||||
Note 3 | Equipment | ||||||||||
30-Sep-13 | |||||||||||
Accumulated | |||||||||||
Cost | Depreciation | Net | |||||||||
Computer equipment | $ | 5,631 | $ | 5,631 | $ | - | |||||
30-Sep-12 | |||||||||||
Accumulated | |||||||||||
Cost | Depreciation | Net | |||||||||
Computer equipment | $ | 5,631 | $ | 5,055 | $ | 576 |
Derivative_Liabilities
Derivative Liabilities | 12 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Derivative Liabilities [Text Block] | ' | |||||||
Note 4 | Derivative Liabilities | |||||||
During the year ended September 30, 2013, the Company issued an aggregate of 6,448,966 share purchase warrants that are required to be accounted for as liabilities pursuant to ASC 815 because the terms of the warrants contain provisions that are in violation of the fixed for fixed criteria of that guidance such that the warrant agreements provide the holder with a full ratchet down adjustment to the exercise price such that in the event the Company, during the term of the warrants, issues common stock or common stock equivalents at a price per share lower than the exercise price of the warrants, the exercise price of the warrants will be adjusted to equal the price at which the new common stock or common stock equivalents are issued. | ||||||||
At September 30, 2013, these share purchase warrants were still outstanding and were being accounted for as liabilities carried at fair value. | ||||||||
During the year ended September 30, 2012, the Company had derivative liabilities that consisted of embedded conversion features in the Company’s convertible promissory notes. | ||||||||
Pursuant to the guidance of ASC 815, these derivative instruments are required to be recorded as liabilities on the balance sheet measured at fair value and are marked-to-market at each balance sheet date with the change in fair value being recorded in the consolidated statements of operations as other income or expense. | ||||||||
A summary of the Company’s derivative liabilities for the years ended September 30, 2013 and 2012 is as follows: | ||||||||
2013 | 2012 | |||||||
Balance, beginning of the period | $ | - | $ | 67,500 | ||||
Fair value at issuance of derivative liability | 919,000 | - | ||||||
Change in fair value of derivative liability | (15,000 | ) | (67,500 | ) | ||||
Balance, end of the period | $ | 904,000 | $ | - | ||||
The convertible promissory notes containing embedded conversion features that were required to be separately accounted for as derivative liabilities matured during the year ended September 30, 2012 and consequently, the liability was extinguished as at September 30, 2012. |
Promissory_Notes_Payable
Promissory Notes Payable | 12 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Promissory Notes Payable [Text Block] | ' | ||||||||||||||||
Note 5 | Promissory Notes Payable | ||||||||||||||||
September 30, | |||||||||||||||||
2013 | 2012 | ||||||||||||||||
Promissory note dated June 6, 2012 bearing interest at 8% per annum, due on demand | $ | - | $ | 49,000 | |||||||||||||
Promissory note dated June 26, 2012 bearing interest at 8% per annum, due on demand | - | 250,000 | |||||||||||||||
Promissory note dated December 31, 2012 bearing interest at 12% per annum, due on December 31, 2013 | 100,000 | - | |||||||||||||||
Promissory note dated January 9, 2013 with a principal balance of $84,060 (CDN$86,677), bearing interest at 12% per annum, secured by all the present and future assets of the Company; due on demand | 84,060 | - | |||||||||||||||
Promissory note dated January 9, 2013 with a principal balance of $26,803 (CDN$27,639), bearing interest at 12% per annum, secured by all the present and future assets of the Company; due on demand | 26,803 | - | |||||||||||||||
210,863 | 299,000 | ||||||||||||||||
Less: current portion | (210,863 | ) | (299,000 | ) | |||||||||||||
$ | - | $ | - | ||||||||||||||
On June 6, 2012, the Company issued a promissory note having a principal balance of $49,000 with terms that included interest at 8% per annum and matured on December 3, 2012. On July 5, 2013, this note, along with accrued interest of $3,200, was settled in exchange for 130,501 units of the Company. Each unit consisted of one share of common stock of the Company and one share purchase warrant, with each warrant entitling the holder thereof to purchase one share of common stock at a price of $0.75 per share for a period of five years from the date of issuance. In connection with the issuance of this note, the Company paid a finder’s fee totaling $4,900 which was deferred and amortized to income using the effective interest method over the terms of the note. As at September 30, 2013, there remained an unamortized balance of $Nil (September 30, 2012: $1,215) in respect of this deferred financing charge. | |||||||||||||||||
On June 26, 2012, the Company issued a promissory note having a principal balance of $250,000 with terms that included interest at 8% per annum and matured on March 31, 2013. On July 5, 2013, this note, along with accrued interest of $15,233, was settled in exchange for 663,082 units of the Company. Each unit consisted of one share of common stock of the Company and one share purchase warrant, with each warrant entitling the holder thereof to purchase one share of common stock at a price of $0.75 per share for a period of five years from the date of issuance. | |||||||||||||||||
On October 17, 2012, the Company issued a promissory note having a principal balance of $150,000 with terms that included interest at 8% per annum and matured on March 31, 2013. On July 5, 2013, this note, along with accrued interest of $5,425 was settled in exchange for 388,562 units of the Company. Each unit consisted of one share of common stock of the Company and one share purchase warrant, with each warrant entitling the holder thereof to purchase one share of common stock at a price of $0.75 per share for a period of five years from the date of issuance. | |||||||||||||||||
On November 14, 2012, the Company issued a promissory note having a principal balance of $50,000 with terms that included interest at 8% per annum and matured on March 31, 2013. On July 5, 2013, this note, along with accrued interest of $1,501 was settled in exchange for 128,753 units of the Company. Each unit consisted of one share of common stock of the Company and one share purchase warrant, with each warrant entitling the holder thereof to purchase one share of common stock at a price of $0.75 per share for a period of five years from the date of issuance. | |||||||||||||||||
On December 31, 2012, the Company issued a promissory note having a principal balance of $100,000 with terms that included interest at 12% per annum and matured on June 30, 2013, in exchange for an accounts payable owing in respect of unpaid consulting fees. . This note was not repaid on June 30, 2013 and the maturity date has been extended to December 31, 2013. | |||||||||||||||||
On February 8, 2013, the Company issued a promissory note having a principal balance of $50,000 with terms that included interest at 10% per annum and matured on June 8, 2013. On July 5, 2013, this note, along with accrued interest of $699 was settled in exchange for 126,747 units of the Company. Each unit consisted of one share of common stock of the Company and one share purchase warrant, with each warrant entitling the holder thereof to purchase one share of common stock at a price of $0.75 per share for a period of five years from the date of issuance. | |||||||||||||||||
On January 9, 2013, the Company issued two promissory notes (the “Secured Notes”); | |||||||||||||||||
a) | The Company issued a promissory note in the amount of $87,865 (CDN$86,677) to the former President, Secretary, Treasurer, CFO and director of the Company (the “President”) in exchange for unpaid consulting fees owing to the President. The note is bearing interest at 12% per annum and was due June 30, 2013. | ||||||||||||||||
b) | The Company issued a promissory note in the amount of $28,017 (CDN$27,639) to a former director of the Company (the “Director”) in exchange for unpaid consulting fees owing to the Director. The note is bearing interest at 12% per annum and was due June 30, 2013. | ||||||||||||||||
The Secured Notes are secured by a right to delay the transfer of any or all of the Company’s assets until the obligations of the Secured Notes are satisfied, including a restriction on the transfer of cash by the Company and a security interest over the intellectual property of the Company. The security interests of the Secured Notes is ranked senior to any and all security interests granted prior to the issuance of the notes and to all subsequent security interests granted, unless the holders agree in writing to other terms. | |||||||||||||||||
In addition, if the promissory notes are not repaid within 10 days of their maturity dates, they shall bear late fees in addition to interest accruing, at a rate of $100 per day per note. | |||||||||||||||||
In an event of default by the Company under the terms of the promissory notes, the notes shall bear additional late fees of $500 per day per note. | |||||||||||||||||
Subsequent to the issuance of these promissory notes, the President resigned as President, Secretary, Treasurer, CFO and director of the Company and the Director resigned as director of the Company. | |||||||||||||||||
The Company did not repay the notes on June 30, 2013. The Company has disputed the issuance of the Secured Notes and should there be an attempt to enforce the Secured Notes or collection on them, the Company will consider a legal remedy. The Company had not accrued any late fees in connection with these promissory notes as at September 30, 2013 as the Company does not consider these amounts to be legally enforceable. | |||||||||||||||||
Extinguishment of promissory notes payable and accounts payable | |||||||||||||||||
On July 5, 2013, the Company issued equity units in settlement of certain of its promissory notes and trade accounts payable. Each unit consisted of one common share and common share purchase warrant entitling the holder to purchase an additional common share at $0.75 until July 5, 2018. | |||||||||||||||||
The promissory note and accounts payable settlements are summarized as follows: | |||||||||||||||||
Amount Settled | Units issued | ||||||||||||||||
Accrued | Loss on | ||||||||||||||||
Date of Note | Principal | Interest | Number | Fair Value | Settlement | ||||||||||||
Promissory notes payable | |||||||||||||||||
6-Jun-12 | 49,000 | 3,200 | 130,501 | 98,205 | 46,005 | ||||||||||||
26-Jun-12 | 250,000 | 15,233 | 663,082 | 498,972 | 233,739 | ||||||||||||
17-Oct-12 | 150,000 | 5,425 | 388,562 | 292,394 | 136,969 | ||||||||||||
14-Nov-12 | 50,000 | 1,501 | 128,753 | 96,887 | 45,386 | ||||||||||||
8-Feb-13 | 50,000 | 699 | 126,747 | 95,377 | 44,678 | ||||||||||||
549,000 | 26,058 | 1,437,645 | 1,081,835 | $ | 506,777 | ||||||||||||
Accounts payable | 1,108,506 | - | 2,771,265 | 2,085,386 | 976,880 | ||||||||||||
$ | 1,657,506 | $ | 26,058 | 4,208,910 | $ | 3,167,221 | $ | 1,483,657 | |||||||||
The fair value of each unit issued was determined to be $0.753 determined by aggregating (i) the fair value of $0.61 for the Company’s common shares based on their quoted market price on the date of settlement and (ii) the fair value of $0.143 for each warrant included in the Company’s units. The fair value of the Company’s warrants was determined using the binomial option pricing model with the following assumptions: | |||||||||||||||||
Stock price | $0.61 | ||||||||||||||||
Exercise price | $0.75 | ||||||||||||||||
Expected volatility | 81.57% | ||||||||||||||||
Risk-free discount rate | 0.28% | ||||||||||||||||
Expected term | 1.49 years | ||||||||||||||||
Expected dividend yield | 0.00% | ||||||||||||||||
The loss on settlement of debt was reduced by an amount of $11,449 relating to the interest that accrued on the promissory notes that was forgiven upon settlement of the notes payable in exchange for shares. |
Capital_Stock
Capital Stock | 12 Months Ended | ||
Sep. 30, 2013 | |||
Capital Stock [Text Block] | ' | ||
Note 6 | Capital Stock | ||
On May 24, 2006, the board of directors approved a six (6) for one (1) forward split of the authorized issued and outstanding common stock. The Company’s authorized capital increased from 25,000,000 shares of common stock to 150,000,000 shares of common stock. | |||
On September 24, 2007, the Company issued 222,222 common shares at $3.60 per share for a total of $800,000 for research and development expenses. The common shares were recorded based upon the quoted market price of the Company’s common stock on the agreement date. | |||
On September 25, 2007, the Company settled a loan payable in the amount of $333,000 by issuing 92,500 common shares at $3.60 per share, being the quoted market price of the Company’s common stock on the settlement date. | |||
On December 10, 2007, the Company issued 150,000 units at $3.50 per unit for proceeds of $525,000. Each unit consisted of one common share and one common share purchase warrant entitling the holder to purchase an additional common share at $5.00 per share until December 10, 2009. | |||
On December 18, 2007, the Company issued 10,000 shares at $4.50 per share for a total of $45,000 pursuant to an agreement to settle a debt and issued 50,000 shares at $3.86 per share for a total of $193,000 pursuant to a consulting agreement. The Company recorded compensation expense of $65,000 in respect of these issuances based on the excess of the fair value of these shares over the balances at which they were recorded by the Company. | |||
On May 15, 2008, the Company issued 65,000 common shares at $5.24 per share for a total of $340,600 to its former CEO in accordance with the terms of a severance agreement upon the termination of his services. The common shares were recorded based upon the quoted market price of the Company’s common stock on the agreement date. | |||
On August 19, 2008, the Company issued 25,000 common shares at $5.07 per share for a total of $126,750 to a director of the Company pursuant to an agreement to provide consulting services. The common shares were recorded based upon the quoted market price of the Company’s common stock on the agreement date. | |||
On August 19, 2008, the Company issued 142,698 units at $4.25 per unit for proceeds of $606,467 pursuant to private placement agreements. Each unit consisted of one common share and one common share purchase warrant entitling the holder to purchase an additional common share at $5.00 per share until August 19, 2009. | |||
On November 20, 2008, the Company issued 25,000 common shares at $2.63 per share for a total of $65,750 to a director of the Company pursuant to an agreement to provide consulting services. The common shares were recorded based upon the quoted market price of the Company’s common stock on the issuance date. | |||
On February 20, 2009, the Company issued 25,000 common shares at $2.50 per share for a total of $62,500 to a director of the Company pursuant to an agreement to provide consulting services. The common shares were recorded based upon the quoted market price of the Company’s common stock on the issuance date. | |||
On March 6, 2009, the Company issued 89,148 units at $2.25 per unit for proceeds of $200,583 pursuant to private placement agreements. Each unit consisted of one common share and one common share purchase warrant entitling the holder to purchase an additional common share at $4.00 per share until March 6, 2010. | |||
On March 20, 2009, the Company issued 10,800 units at $2.25 per unit for proceeds of $24,300 pursuant to private placement agreements. Each unit consisted of one common share and one common share purchase warrant entitling the holder to purchase an additional common share at $4.00 per share until March 20, 2010. | |||
On March 20, 2009, the Company issued 2,500 common shares at $2.00 per share for a total of $5,000 to a public relations consultant pursuant to an agreement to provide consulting services. The common shares were recorded based upon the quoted market price of the Company’s common stock on the issuance date. | |||
On May 14, 2009, the Company entered into a revised consulting agreement with a director whereby the consultant returned 75,000 common shares to the Company for cancellation. The return of shares was recorded in the same amount at which they were originally issued. On June 11, 2009 the Company issued 36,000 units at $2.25 per unit for proceeds of $81,000 pursuant to private placement agreements. Each unit consisted of one common share and one common share purchase warrant entitling the holder to purchase an additional common share at $4.00 per share until June 11, 2010. The Company paid finders’ fees in the amount of $8,100 in relation to this private placement. | |||
On June 11, 2009 the Company issued 29,227 common shares at $2.25 per share for service rendered by consultants. The common shares were recorded based upon the fair value of the Company’s common stock on the issuance date of the shares. | |||
On June 19, 2009, the Company issued 495,556 units at $2.25 per unit for total proceeds of $1,115,000 pursuant to private placement agreements. Each unit consisted of one common share and one and one-half of a common share purchase warrant entitling the holder to purchase additional common shares at $2.25 per share until June 19, 2011. | |||
On June 26, 2009, the Company issued 22,222 common shares at $2.51 per share for finder’s fees related to the issuance of a $500,000 note payable. The common shares were recorded based upon the quoted market price of the Company’s common stock on the issue date. | |||
On August 19, 2009, the Company issued 128,888 units at $2.25 per unit for total proceeds of $289,998. Of these placements, 40,000 units consisted of one common share and one share purchase warrant entitling the holder to purchase an additional common share at $4.00 per share until July 9, 2010 and 88,888 Units consisted of one common share and one and one- eighth share purchase warrant entitling the holder to purchase an additional common shares at $2.25 per share until August 4, 2011. The Company paid finders’ fees totalling $19,000 in respect of these private placements. | |||
On October 2, 2009 the Company issued 266,666 units at $2.25 per unit for proceeds of $600,000 pursuant to private placement agreements. Each unit consisted of one common share and one and one-eighth common share purchase warrant entitling the holder to purchase an additional common shares at $2.25 per share until October 2, 2011. The Company had received $300,000 of this amount in the year ended September 30, 2010. | |||
On February 2, 2010 the Company issued 49,505 common shares of the Company, at their fair value of $2.02 per share pursuant to an agreement with a former officer to settle an outstanding amount owed. | |||
On April 9, 2010, the Company issued 92,499 units at $2.60 per unit for proceeds of $240,498 pursuant to private placement agreements. Each unit consisted of one common share and one-half common share purchase warrant entitling the holder to purchase additional common shares at $3.50 per share until April 9, 2011. | |||
On April 30, 2010, the Company issued 9,825 common shares of the Company, at $2.85 per share as consideration for terminating a consulting agreement and for services rendered under the agreement. The common shares were recorded based upon the quoted market price of the Company’s common stock on the date of the termination of the agreement. | |||
On June 29, 2010, the Company issued 941,000 units at $2.50 per unit for total proceeds of $2,352,500 pursuant to private placement agreements. Each unit consisted of one common share and one-half of a common share purchase warrant entitling the holder to purchase additional common shares at $3.50 per share until December 29, 2011. | |||
On July 5, 2010, the Company issued 400,000 units in settlement of $1,000,000 owing to a creditor. Each unit consisted of one common share and one-half common share purchase warrant entitling the holder to purchase additional common shares at 3.50 per share until January 5, 2012. The fair value of the units issued was determined to be $1,444,000 on the date they were issued and thus the Company recorded a loss on settlement of accounts payable of $444,000 with a corresponding credit to additional paid-in capital of the same amount on date of issuance. The fair value of the shares included in the units was determined with reference to their quoted market price and the value of the warrants was determined using the Black-Scholes model with the following assumptions: exercise price - $3.50, stock price - $3.15, expected volatility – 68.45%, expected life – 1.5 years, dividend yield – 0.00%. | |||
On September 3, 2010, the Company issued 163,000 units at $2.75 per unit for proceeds of $448,250 pursuant to private placement agreements. Each unit consisted of one common share and one-half common share purchase warrant entitling the holder to purchase additional common shares at $3.75 per share until March 3, 2012. | |||
On September 3, 2010, the Company issued 9,000 units at $2.75 per unit for finder’s fees related to the private placement of the same date. Each unit consisted of one common share and one-half common share purchase warrant entitling the holder to purchase additional common shares at $3.75 per share until March 3, 2012. | |||
On September 30, 2010, the Company issued 510,638 common shares at $2.35 per share pursuant to the terms of a convertible note payable. | |||
On September 30, 2010, the Company issued 82,310 units at $2.25 per unit pursuant to the terms of convertible notes payable. Each unit consisted of one common share and one-half common share purchase warrant entitling the holder to purchase additional common shares at $3.50 per share until September 30, 2011. | |||
On September 30, 2010, the Company issued 245,748 units at $2.25 per unit pursuant to the terms of convertible notes payable. Each unit consisted of one common share and one common share purchase warrant entitling the holder to purchase additional common shares at $3.00 per share until September 30, 2012. | |||
On November 18, 2010, the Company issued 393,846 units at $2.75 per unit for proceeds of $1,083,075 pursuant to a private placement agreement. Each unit consisted of one common share and one-half common share purchase warrant entitling the holder to purchase additional common shares at $4.50 per share until May 18, 2012. The Company paid a finder’s fee totalling $65,363 in respect of this private placement. | |||
On November 18, 2010, the Company issued 3,636 units at $2.75 per unit for finder’s fees related to the private placement of the same date. Each unit consisted of one common share and one-half common share purchase warrant entitling the holder to purchase additional common shares at $4.50 per share until May 18, 2012. | |||
On November 18, 2010, the Company issued 853,075 units in the conversion of two notes payable originally convertible at $2.50. The Company recorded debt conversion expense of $504,160, related to the fair value of the additional units issued as a result of converting at the lower conversion price. Each unit consisted of one common share and one common share purchase warrant entitling the holder to purchase additional common shares at $3.00 per share until November 18, 2012. The fair value of the shares included in the units was determined with reference to their quoted market price and the value of the warrants was determined using the Black-Scholes model with the following assumptions: exercise price - $3.00, stock price - $4.12, expected volatility – 78.33%, expected life – 2.0 years, dividend yield – 0.00%, risk-free rate – 0.52%. | |||
On November 18, 2010, the Company issued 145,063 shares of common stock at their fair value of $4.12 per share based on their quoted market price pursuant to settling non- convertible interest bearing notes payable outstanding in the amount of $398,922, including accrued interest of $26,032. The Company recorded a loss on settlement of debt of $198,738 based on the difference between the carrying value of the debt settled and the fair value of the shares issued. | |||
On November 18, 2010, the Company issued 181,818 shares of common stock at their fair value of $4.12 per share based on the quoted value of units issued in a private placement on the same date to one creditor in settlement of $500,000 of debt owing. The Company recorded a loss on settlement of accounts payable of $249,090 based on the difference of the carrying value of the account payable and the fair value of the shares issued. | |||
On November 25, 2010, the Company issued 29,851 units at $3.35 per unit for proceeds of $100,000 pursuant to a private placement agreement. Each unit consisted of one common share and one-half common share purchase warrant entitling the holder to purchase additional common shares at $4.50 per share until November 25, 2012. | |||
On November 25, 2010, the Company issued 2,985 units at $3.35 per unit for finder’s fees related to the private placement of the same date. Each unit consisted of one common share and one-half common share purchase warrant entitling the holder to purchase additional common shares at $4.50 per share until November 25, 2012. | |||
On February 1, 2011, the Company issued 61,014 units at $3.75 per unit for proceeds of $228,800 pursuant to a private placement agreement. Each unit consisted of one common share and one-half common share purchase warrant entitling the holder to purchase additional common shares at $5.25 per share until August 1, 2012. | |||
On May 3, 2011, the Company issued 33,334 units at $3.00 per unit for proceeds of $100,000 pursuant to a private placement agreement. Each unit consisted of one common share and one-half common share purchase warrant entitling the holder to purchase additional common shares at $4.00 per share until April 20, 2013. | |||
On June 19, 2011, the Company issued 700,000 common shares at $2.25 per share for proceeds of $1,575,000 pursuant to the exercise of warrants. | |||
On September 26, 2011, the Company issued 650,000 units in settlement of $975,000 of debt owing. Each unit consisted of one common share and one-half common share purchase warrant entitling the holder to purchase additional common shares at $2.00 per share until September 26, 2012. The Company recorded a loss on settlement of accounts payable in the amount of $84,963 based on the fair value of shares being $975,000 at their issuance and the fair value of the warrants determined to be $84,963. The fair value of the shares included in the units was determined with reference to their quoted market price and the value of the warrants was determined using the Black-Scholes model with the following assumptions: exercise price - $2.00, stock price - $1.50, expected volatility – 69%, expected life – 1.0 years, dividend yield – 0.00%, risk-free interest rate – 0.10%. | |||
On December 6, 2011, the Company issued 615,600 units at $1.25 per unit for proceeds of $769,500 pursuant to private placement agreements. Each unit consisted of one common share and one-half common share purchase warrant entitling the holder to purchase additional common shares at $2.00 per share until December 6, 2012. The Company paid finder’s fees of $77,000 in connection with this private placement. | |||
On February 9, 2012 the Company issued 8,000 units for service rendered by a director and officer of the Company. Each unit consisted of one common share and one-half common share purchase warrant entitling the holder to purchase additional common shares at $2.00 per share until February 9, 2013. The fair value of the units issued was determined to be $15,896 on the date they were issued and the Company recorded consulting fees of $15,896 on the statement of operations for the year ended September 30, 2012. The fair value of the shares included in the units was determined with reference to their quoted market price and the value of the warrants was determined using the Black-Scholes model with the following assumptions: exercise price - $2.00, stock price - $1.74, expected volatility – 84.88%, expected life – 1.0 years, risk free interest rate – 0.15%, dividend yield – 0.00%. | |||
On February 9, 2012, the Company issued 270,000 units at $1.25 per unit for proceeds of $337,500 pursuant to private placement agreements. Each unit consisted of one common share and one-half common share purchase warrant entitling the holder to purchase additional common shares at $2.00 per share until February 9, 2013. The Company paid a finder’s fee of $33,750 in connection with this private placement. | |||
On May 31, 2012, the Company issued 2,700,513 units in settlement of $1,297,889 in promissory notes and $52,367 of accrued interest on these notes, which was included in accounts payable and accrued liabilities Each unit consisted of one common share and one common share purchase warrant entitling the holder to purchase additional common shares at $0.75 per share until November 30, 2013. | |||
On June 26, 2012, the Company agreed to issue 75,000 common shares to the former president of the Company for past services and in final settlement of a consulting agreement dated February 1, 2007. These shares were issued on July 12, 2012. | |||
On July 5, 2013, the Company issued 4,208,910 units in settlement of $549,000 in promissory notes, $26,058 of accrued interest on these notes, which was included in accounts payable and accrued liabilities, and $1,108,506 in other accounts payable and accrued liabilities. Each unit consisted of one common share and one common share purchase warrant entitling the holder to purchase additional common shares at $0.75 per share until July 5, 2018 (Note 5). | |||
On July 5, 2013, the Company issued 2,196,133 units at $0.40 per unit for gross proceeds of $878,453 pursuant to private placement agreements. Each unit consisted of one common share and one common share purchase warrant entitling the holder to purchase additional common shares at $0.75 per share until July 5, 2018. The Company paid finder’s fees of $89,680 and issued warrants to purchase 43,923 shares of common stock at $0.75 per share until July 5, 2018 in connection with this private placement. In addition, the Company incurred share issuance costs of $16,494. | |||
All of the 6,448,966 warrant agreements issued on July 5, 2013 contain the following provisions: | |||
(i) | a full ratchet down adjustment to the exercise price such that in the event the Company, during the term of the warrants, issues common stock or common stock equivalents at a price per share lower than the exercise price of the warrants, the exercise price of the warrants will be adjusted to equal the price at which the new common stock or common stock equivalents are issued; | ||
(ii) | a put option whereby in the event of certain fundamental transactions, as defined in the warrant agreements, the Company may be required to pay the Holder an amount of cash equal to the value of the warrant as determined in accordance with the Black Scholes option pricing model, for each warrant held by the Holder; and | ||
(iii) | a contingent call provision whereby the Company may have the option to call for cancellation all of any portion of the warrants for consideration equal to $0.001 per share, provided the quoted market price of the Company’s common stock exceeds $1.50 for a period of twenty consecutive trading days, subject to certain minimum volume restrictions and other restrictions as provided in the warrant agreements. | ||
Common stock to be issued | |||
During the year ended September 30, 2013, the Company received $60,000 in share subscriptions in respect of the issuance of 120,000 units at $0.50 per unit. Each unit will consist of one common share and one common share purchase warrant entitling the holder to purchase additional common shares at $1.00 per share for a period of five years from the date of issuance. |
Equity_Line_of_Credit
Equity Line of Credit | 12 Months Ended | |
Sep. 30, 2013 | ||
Equity Line of Credit [Text Block] | ' | |
Note 7 | Equity Line of Credit | |
On July 5, 2013, the Company entered into a $10,000,000 purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC, (“Lincoln Park”) an Illinois limited liability company (the “Financing”) pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $10,000,000 in value of its shares of common stock from time to time over a 36 month period. In connection with the Financing, the Company also entered into a registration rights agreement with Lincoln Park whereby the Company agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) covering the shares of the Company’s common stock that may be issued to Lincoln Park under the Purchase Agreement. | ||
The Company will determine, at its own discretion, the timing and amount of its sales of common stock, subject to certain conditions and limitations. The purchase price of the shares that may be sold to Lincoln Park under the Purchase Agreement will be based on the market price of the Company’s shares of common stock immediately preceding the time of sale without any fixed discount, provided that in no event will such shares be sold to Lincoln Park when the closing sale price is less than $0.50 per share. There are no upper limits on the per share price that Lincoln Park may pay to purchase such common stock. The purchase price will be equitably adjusted for any reorganization, recapitalization, non-cash dividend, stock split or similar transaction occurring during the business days used to compute such price. | ||
Pursuant to the Purchase Agreement, Lincoln Park initially purchased 250,000 shares of the Company’s common stock for $100,000. In consideration for entering into the Purchase Agreement, the Company issued to Lincoln Park 341,858 shares of common stock as a commitment fee and shall issue up to 133,409 shares pro rata, when and if, Lincoln Park purchases at the Company’s discretion the remaining $10,000,000 aggregate commitment. The Purchase Agreement may be terminated by the Company at any time at its discretion without any cost to the Company. | ||
On October 23, 2013, the registration statement was declared effective by the SEC. | ||
The Company incurred $71,335 in direct expenses in connection with the Purchase Agreement and registration statement. These were recorded as share issuance costs as a charge against additional paid in capital during the year ended September 30, 2013. |
Related_Party_Transactions
Related Party Transactions | 12 Months Ended | ||||||||||
Sep. 30, 2013 | |||||||||||
Related Party Transactions [Text Block] | ' | ||||||||||
Note 8 | Related Party Transactions | ||||||||||
The following amounts have been donated to the Company by the directors: | |||||||||||
23-Jan-04 | |||||||||||
Year ended September 30, | (Date of Inception) | ||||||||||
2013 | 2012 | to September 30, 2013 | |||||||||
Management fees | $ | - | $ | - | $ | 14,625 | |||||
Rent | - | - | 3,750 | ||||||||
Debt forgiven by directors | - | - | 33,666 | ||||||||
$ | - | $ | - | $ | 52,041 | ||||||
During the year ended September 30, 2013, the Company was charged consulting fees totaling $81,072 (2012: $479,434) by directors, officers and a significant shareholder of the Company. As at September 30, 2013, included in accounts payable and accrued liabilities is $30,447 (2012: $127,452) owing to directors and officers of the Company and a former director and officer of the Company. | |||||||||||
On July 5, 2013, pursuant to an employment agreement with the newly appointed President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer, and Director, of the Company, the Company: | |||||||||||
i) | granted 2,000,000 fully vested share purchase options exercisable at $0.40 per share until July 5, 2023. The Company recognized stock based compensation expense of $1,002,500 (2012: $Nil) during the year ended September 30, 2013 in connection with these options. | ||||||||||
ii) | issued 4,000,000 shares of restricted common stock that vest as follows: | ||||||||||
• | 25% upon the Company starting a Phase Ib/IIb human study | ||||||||||
• | 25% upon the Company in-licensing additional assets in clinical or pre-clinical stage | ||||||||||
• | 25% upon the Company securing additional non-dilutive equity funding in 2013 of at least $5,000,000 with a share price higher than the previous funding. | ||||||||||
• | 25% upon the Company obtaining a listing on a major stock exchange. | ||||||||||
No stock-based compensation has been recorded in connection with the issuance of these shares in the financial statements for the year ended September 30, 2013 as none of the performance conditions have yet been met. |
Commitments
Commitments | 12 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Commitments [Text Block] | ' | |||||||||||||||
Note 9 | Commitments | |||||||||||||||
a) | Share Purchase Warrants | |||||||||||||||
A summary of the Company’s share purchase warrants outstanding is presented below: | ||||||||||||||||
Weighted | ||||||||||||||||
Average | ||||||||||||||||
Exercise | ||||||||||||||||
Number of Shares | Price | |||||||||||||||
Balance, September 30, 2011 | 2,655,479 | $ | 3.16 | |||||||||||||
Expired | (1,552,651 | ) | $ | 3.16 | ||||||||||||
Issued | 3,147,313 | $ | 0.93 | |||||||||||||
Balance, September 30, 2012 | 4,250,141 | $ | 1.16 | |||||||||||||
Expired | (1,549,628 | ) | $ | 2.56 | ||||||||||||
Issued | 6,448,966 | $ | 0.75 | |||||||||||||
Balance, September 30, 2013 | 9,149,479 | $ | 0.75 | |||||||||||||
At September 30, 2013, the Company has 9,149,479 currently exercisable share purchase warrants outstanding as follows: | ||||||||||||||||
Number | Exercise Price | Expiry Date | ||||||||||||||
2,700,513 | $ | 0.75 | 30-Nov-13 | |||||||||||||
6,448,966 | $ | 0.75 | 5-Jul-18 | |||||||||||||
9,149,479 | ||||||||||||||||
During the year ended September 30, 2012, the exercise price and expiry of 200,000 warrants exercisable at $3.50 and expiring January 5, 2012 were modified and extended such that these warrants were exercisable at $1.50 until January 5, 2013. The fair value of this modification was determined to be $80,200 and was determined using the Black-Scholes option pricing model using the following weighted average assumptions: risk-free interest rate: 0.11%, expected life: 1.0 year, annualized volatility: 79.46%, dividend rate: 0%. | ||||||||||||||||
b) | Stock–based Compensation Plan | |||||||||||||||
In April, 2007, the Company adopted a stock option plan which provides for the granting of stock options to selected directors, officers, employees or consultants in an aggregate amount of up to 3,000,000 common shares of the Company and, in any case, the number of shares to be issued to any one individual pursuant to the exercise of options shall not exceed 10% of the issued and outstanding share capital. The granting of stock options, exercise prices and terms are determined by the Company's Board of Directors. If no vesting schedule is specified by the Board of Directors on the grant of options, then the options shall vest over a 4 -year period with 25% of the options granted vesting each year commencing 1 year from the grant date. For stockholders who have greater than 10% of the outstanding common shares of the Company and who have granted options, the exercise price of their options shall not be less than 110% of the fair of the stock on grant date. Otherwise, options granted shall have an exercise price equal to their fair value on grant date. | ||||||||||||||||
On February 2, 2011, the Company amended and restated the 2007 stock option plan to increase the number of options authorized to 4,000,000. | ||||||||||||||||
A summary of the status of Company’s outstanding stock purchase options for the year ended September 30, 2013 is presented below: | ||||||||||||||||
Weighted | Weighted | |||||||||||||||
Number of | Average | Average Grant | ||||||||||||||
Shares | Exercise Price | Date fair value | ||||||||||||||
Outstanding at September 30, 2011 | 2,375,000 | $ | 3.18 | |||||||||||||
Forfeited | (1,100,000 | ) | $ | 2.82 | ||||||||||||
Granted | 500,000 | $ | 1.5 | $ | 0.72 | |||||||||||
Outstanding at September 30, 2012 | 1,775,000 | $ | 2.94 | |||||||||||||
Expired | (550,000 | ) | $ | 3.86 | ||||||||||||
Forfeited | (150,000 | ) | $ | 3.72 | ||||||||||||
Granted | 2,000,000 | $ | 0.4 | $ | 0.5 | |||||||||||
Outstanding at September 30, 2013 | 3,075,000 | $ | 1.26 | |||||||||||||
Exercisable at September 30, 2013 | 2,305,000 | $ | 0.79 | |||||||||||||
Exercisable at September 30, 2012 | 905,000 | $ | 2.81 | |||||||||||||
At September 30, 2013, the following stock options were outstanding: | ||||||||||||||||
Number of Shares | Aggregate | Remaining | ||||||||||||||
Number | Exercise | Intrinsic | Contractual | |||||||||||||
Total | Vested | Price | Expiry Date | Value | Life (yrs) | |||||||||||
150,000 (1) | 150,000 | $ | 3.1 | 30-Jun-14 | - | 0.75 | ||||||||||
500,000 (2) | - | $ | 2.5 | 19-Oct-13 | - | 0.05 | ||||||||||
5,000 (3) | 5,000 | $ | 2.5 | 2-Mar-14 | - | 0.42 | ||||||||||
50,000 (4) | 50,000 | $ | 3.5 | 30-Jun-14 | - | 0.75 | ||||||||||
100,000 (5) | 100,000 | $ | 3.67 | 30-Mar-16 | - | 2.5 | ||||||||||
270,000 (6) | - | $ | 3 | 8-Feb-17 | - | 3.36 | ||||||||||
2,000,000 (7) | 2,000,000 | $ | 0.4 | 5-Jul-23 | 500,000 | 9.77 | ||||||||||
3,075,000 | 2,305,000 | 500,000 | ||||||||||||||
The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market price of the Company’s stock for the options that were in-the-money at September 30, 2013. | ||||||||||||||||
-1 | As at September 30, 2013 and 2012, these options had fully vested. During the year ended September 30, 2012, the expiry of these options was extended from June 3, 2013 to June 30, 2014. The fair value of this modification was determined to be $18,600 and was determined using the Black Scholes option pricing model using the following weighted average assumptions: risk-free interest rate: 0.31%, expected life: 2.0 years, annualized volatility: 84.74%, dividend rate: 0%. The Company did not recognize any stock-based compensation for these options during the year ended September 30, 2013 (2012: $18,600). | |||||||||||||||
-2 | As at September 30, 2013 and 2012, none of these options have vested. The options vest as to 100,000 per compound entered into a phase II trial. The fair value of these options was calculated to be $740,000, which the Company has not yet recognized in the financial statements as the performance conditions have not yet been met. | |||||||||||||||
-3 | As at September 30, 2013 and 2012, these options had fully vested. The Company did not recognize any stock-based compensation for these options during the year ended September 30, 2013 (2012: $nil). | |||||||||||||||
-4 | As at September 30, 2013 and 2012, these options had fully vested. The Company did not recognize any stock-based compensation during the year ended September 30, 2013 (2012: $nil). During the year ended September 30, 2012, the expiry of these options was shortened from June 29, 2015 to June 30, 2014. The Company did not recognize any stock based compensation expense in connection with this modification because the fair value of the modified options was less than the fair value of the options under the old terms. | |||||||||||||||
-5 | As at September 30, 2013 and 2012, these options had fully vested. The fair value of these options at issuance was calculated to be $267,000. The Company did not recognize any stock-based compensation during the year ended September 30, 2013 (2012: $6,500). | |||||||||||||||
-6 | As at September 30, 2013 and 2012, these options had not vested. The options vest upon one or more compounds: entering Phase II trial – 90,000 options; entering Phase III trial – 90,000 options; and receiving FDA approval – 90,000 options. No stock-based compensation has been recorded in the financial statements as none of the performance conditions have yet been met. | |||||||||||||||
-7 | As at September 30, 2013 these options had fully vested (2012: None of these options had vested). These options were granted during the year ended September 30, 2013 and vested immediately upon granting. The Company recognized stock based compensation expense of $1,002,500 (2012: $Nil) during the year ended September 30, 2013 in connection with these options. | |||||||||||||||
During the year ended September 30, 2013, 150,000 options were forfeited for which the Company had recognized stock-based compensation of $Nil (2012: $163,415) during the year ended September 30, 2013. | ||||||||||||||||
During the year ended September 30, 2012, 1,100,000 options were forfeited for which the Company had recognized stock-based compensation of $33,493 during the year ended September 30, 2012. | ||||||||||||||||
The fair value of stock options granted has been determined using the Black-Scholes option pricing model using the following weighted average assumptions applied to stock options granted during the periods: | ||||||||||||||||
2013 | 2012 | |||||||||||||||
Risk-free interest rate | 2.73% | 0.83% - 2.19% | ||||||||||||||
Expected life of options | 10.0 years | 4.25 - 5.0 years | ||||||||||||||
Annualized volatility | 71.39% | 57.87% - 95.25% | ||||||||||||||
Dividend rate | 0.00% | 0.00% | ||||||||||||||
At September 30, 2013, the following summarizes the unvested stock options: | ||||||||||||||||
Weighted | Weighted | |||||||||||||||
Average | Average | |||||||||||||||
Number of | Exercise | Grant-Date | ||||||||||||||
Shares | Price | Fair Value | ||||||||||||||
Unvested options at September 30, 2011 | 1,445,000 | $ | 3.33 | $ | 2.17 | |||||||||||
Granted | 500,000 | $ | 1.5 | $ | 0.72 | |||||||||||
Forfeited | (900,000 | ) | $ | 2.74 | $ | 1.6 | ||||||||||
Vested | (175,000 | ) | $ | 3.71 | $ | 2.7 | ||||||||||
Unvested options at September 30, 2012 | 870,000 | $ | 2.81 | $ | 1.82 | |||||||||||
Granted | 2,000,000 | $ | 0.4 | $ | 0.5 | |||||||||||
Expired | (100,000 | ) | $ | 3.86 | $ | 2.49 | ||||||||||
Vested | (2,000,000 | ) | $ | 0.4 | $ | 0.5 | ||||||||||
Unvested options at September 30, 2013 | 770,000 | $ | 2.68 | $ | 1.74 | |||||||||||
As at September 30, 2013, there was no unrecognized compensation cost associated with unvested share-based compensation awards that will become vested exclusive of achieving any performance milestones that is expected to be recognized in the current fiscal year. There has been no stock-based compensation recognized in the financial statements for the year ended September 30, 2013 (2012: $nil) for options that will vest upon the achievement of performance milestones because the Company has determined that satisfaction of the performance milestones was not probable. Compensation relating to stock options exercisable upon achieving performance milestones will be recognized in the period the milestones are achieved. | ||||||||||||||||
Stock-based compensation amounts, including those relating to shares issued for services during the years ended September 30, 2013 and 2012, are classified in the Company’s Statement of Operations as follows: | ||||||||||||||||
2013 | 2012 | |||||||||||||||
Consulting fees | $ | - | $ | 312,903 | ||||||||||||
Research and development | - | 80,200 | ||||||||||||||
Salaries and wages | 1,002,500 | - | ||||||||||||||
$ | 1,002,500 | $ | 393,103 |
Income_Taxes
Income Taxes | 12 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Income Taxes [Text Block] | ' | |||||||
Note 10 | Income Taxes | |||||||
The tax effects of the temporary differences that give rise to the Company’s estimated deferred tax assets and liabilities are as follows: | ||||||||
2013 | 2012 | |||||||
Tax rate | 34% | 34% | ||||||
Net operating loss carryforwards | $ | 7,141,000 | $ | 6,775,000 | ||||
Research and development tax credits | 705,000 | 741,000 | ||||||
Foreign exchange | (19,000 | ) | 28,000 | |||||
Accrued bonuses | 34,000 | 34,000 | ||||||
Intangible asset costs | 51,000 | 34,000 | ||||||
Stock-based compensation | 633,000 | - | ||||||
Valuation allowance for deferred tax assets | (8,545,000 | ) | (7,612,000 | ) | ||||
Net deferred tax assets | $ | - | $ | - | ||||
The provision for income taxes differ from the amount established using the statutory income tax rate as follows: | ||||||||
2013 | 2012 | |||||||
Income benefit at statutory rate | $ | (1,258,000 | ) | $ | (2,823,000 | ) | ||
Foreign income taxed at foreign statutory rate | - | (2,000 | ) | |||||
Debt extinguishment | 501,000 | 1,302,000 | ||||||
Research and development tax credit | (17,000 | ) | (175,000 | ) | ||||
Fair value of derivative liability | 7,000 | (23,000 | ) | |||||
Debt accretion | - | 33,000 | ||||||
Other permanent differences | (5,000 | ) | 113,000 | |||||
Adjustment to prior years' tax provision | (161,000 | ) | - | |||||
Change in valuation allowance | 933,000 | 1,575,000 | ||||||
Income Tax Expense | $ | - | $ | - | ||||
As of September 30, 2013, the Company had net operating loss carry-forwards of approximately $21,022,000 (2012: $20,196,000) available to offset future taxable income. The carry-forwards will begin to expire in 2027 unless utilized in earlier years. The Company has not yet filed any tax returns in France as they are not yet due. | ||||||||
The Company evaluates its valuation allowance requirements based on projected future operations. When circumstances change and this causes a change in management’s judgment about the recoverability of deferred tax assets, the impact of the change on the valuation allowance is reflected in current income. Because management of the Company does not currently believe that it is more likely than not that the Company will receive the benefit of these assets, a valuation allowance equal to the deferred tax asset has been established at both September 30, 2013 and 2012. | ||||||||
Uncertain Tax Positions | ||||||||
The Company files income tax returns in the U.S. federal jurisdiction, various state and foreign jurisdictions. The Company’s tax returns are subject to tax examinations by U.S. federal and state tax authorities, or examinations by foreign tax authorities until respective statute of limitation. The Company is subject to tax examinations by tax authorities for all taxation years commencing on or after 2005. |
Supplemental_Cash_Flow_Informa
Supplemental Cash Flow Information | 12 Months Ended | ||
Sep. 30, 2013 | |||
Supplemental Cash Flow Information [Text Block] | ' | ||
Note 11 | Supplemental Cash Flow Information | ||
Investing and financing activities that do not have a direct impact on current cash flows are excluded from the statement of cash flows. | |||
During the year ended September 30, 2013; | |||
a) | The Company issued three promissory notes in the principal amounts of $100,000, $87,865 (CDN$86,677) and $28,017 (CDN$27,639) in exchange for accounts payable owing to three vendors in respect of unpaid consulting fees. | ||
b) | The Company issued 4,208,910 units of the Company at their fair value of $1.02 per unit to settle (i) interest bearing notes payable outstanding in the amount of $549,000 ; (ii) accrued interest in connection with the notes payable of $26,058 included in accounts payable and accrued liabilities; and (iii) accounts payable of $1,108,506. Each unit consisted of one common share and one common share purchase warrant exercisable into one additional common share for $0.75 per share until July 5, 2018. In addition, in connection with the settlement, $11,449 of accrued interest with respect to the notes payable was forgiven. The Company recorded a loss on debt settlement of $1,472,208 as a result of this transaction. | ||
During the year ended September 30, 2012: | |||
a) | The Company issued 544,667 units of the Company at their fair value of $1.918 per unit to settle a convertible interest bearing note payable outstanding in the amount of $272,333, including accrued interest of $22,333 included in accounts payable and accrued liabilities and 2,155,846 units of the Company at their fair value of $1.918 per unit to settle non- convertible interest bearing notes payable outstanding in the amount of $1,077,923 including accrued interest of $30,034 included in accounts payable and accrued liabilities. Each unit consisted of one common share and one common share purchase warrant exercisable into one additional common share for $0.75 per share until November 30, 2013. The Company recorded a loss on debt settlement of $3,829,333 as a result of this transaction. | ||
b) | The Company issued 75,000 common shares at their fair value of $1.00 per share for a total of $75,000 to the former President of the Company pursuant to a severance agreement. |
Summary_of_Significant_Account1
Summary of Significant Accounting Policies (Policies) | 12 Months Ended | ||
Sep. 30, 2013 | |||
Use of Estimates [Policy Text Block] | ' | ||
a) | Use of Estimates | ||
The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to deferred income tax asset valuations, asset impairment, conversion features embedded in convertible notes payable, derivative valuations, stock based compensation and loss contingencies. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. | |||
Principles of Consolidation [Policy Text Block] | ' | ||
b) | Principles of Consolidation | ||
These consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiary, Anavex Life Sciences (France) SA, a company incorporated under the laws of France. All inter-company transactions and balances have been eliminated. | |||
Development Stage Company [Policy Text Block] | ' | ||
c) | Development Stage Company | ||
The Company is devoting substantially all of its present efforts to establish a new business and none of its planned principal operations have commenced. All losses accumulated since inception have been considered as part of the Company’s development stage activities. | |||
Equipment [Policy Text Block] | ' | ||
d) | Equipment | ||
Equipment is recorded at cost and is depreciated at 33% per annum on the straight-line basis. | |||
Impairment of Long-Lived Assets [Policy Text Block] | ' | ||
e) | Impairment of Long-Lived Assets | ||
The Company reviews the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The estimated future cash flows are based upon, among other things, assumptions about future operating performance, and may differ from actual cash flows. Long-lived assets evaluated for impairment are grouped with other assets to the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. If the sum of the projected undiscounted cash flows (excluding interest) is less than the carrying value of the assets, the assets will be written down to the estimated fair value in the period in which the determination is made. | |||
Financial Instruments [Policy Text Block] | ' | ||
f) | Financial Instruments | ||
The carrying value of the Company’s financial instruments, consisting of cash and accounts payable and accrued liabilities approximate their fair value due to the short-term maturity of such instruments. Based on borrowing rates currently available to the Company for similar terms and based on the short term duration of the debt instruments, the carrying value of the promissory notes payable approximate their fair value. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments. | |||
Foreign Currency Translation [Policy Text Block] | ' | ||
g) | Foreign Currency Translation | ||
The functional currency of the Company is the US dollar. Monetary items denominated in a foreign currency are translated into US dollars at exchange rates prevailing at the balance sheet date and non-monetary items are translated at exchange rates prevailing when the assets were acquired or obligations incurred. Foreign currency denominated expense items are translated at exchange rates prevailing at the transaction date. Unrealized gains or losses arising from the translations are credited or charged to income in the period in which they occur. | |||
Research and Development Expenses [Policy Text Block] | ' | ||
h) | Research and Development Expenses | ||
Research and developments costs are expensed as incurred. These expenses are comprised of the costs of the Company’s proprietary research and development efforts, including salaries, facilities costs, overhead costs and other related expenses as well as costs incurred in connection with third-party collaboration efforts. Milestone payments made by the Company to third parties are expensed when the specific milestone has been achieved. | |||
In addition, the Company incurs expenses in respect of the acquisition of intellectual property relating to patents. The probability of success and length of time to developing commercial applications of the drugs subject to the acquired patents and trademarks is difficult to determine and numerous risks and uncertainties exist with respect to the timely completion of the development projects. There is no assurance the acquired patents will ever be successfully commercialized. Due to these risks and uncertainties, the acquisition costs of patents do not meet the definition of an asset and thus are expensed as incurred. | |||
Income Taxes [Policy Text Block] | ' | ||
i) | Income Taxes | ||
The Company has adopted the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. | |||
Basic and Diluted Loss per Share [Policy Text Block] | ' | ||
j) | Basic and Diluted Loss per Share | ||
The basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding. Diluted loss per common share is computed similar to basic loss per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. For the year ended September 30, 2013, loss per share excludes 12,224,479 (2012 – 6,025,141) potentially dilutive common shares (related to outstanding options and warrants) as their effect was anti-dilutive. | |||
Stock-based Compensation [Policy Text Block] | ' | ||
k) | Stock-based Compensation | ||
The Company accounts for all stock-based payments and awards under the fair value based method. | |||
Stock-based payments to non-employees are measured at the fair value of the consideration received, or the fair value of the equity instruments issued, or liabilities incurred, whichever is more reliably measurable. The fair value of stock-based payments to non-employees is periodically re-measured until the counterparty performance is complete, and any change therein is recognized over the vesting period of the award and in the same manner as if the Company had paid cash instead of paying with or using equity based instruments. Compensation costs for stock-based payments with graded vesting are recognized on a straight-line basis. The cost of the stock-based payments to non- employees that are fully vested and non-forfeitable as at the grant date is measured and recognized at that date, unless there is a contractual term for services in which case such compensation would be amortized over the contractual term. | |||
The Company accounts for the granting of share purchase options to employees using the fair value method whereby all awards to employees will be recorded at fair value on the date of the grant. The fair value of all share purchase options are expensed over their vesting period with a corresponding increase to additional paid-in capital. | |||
The Company uses the Black-Scholes option valuation model to calculate the fair value of share purchase options at the date of the grant. Option pricing models require the input of highly subjective assumptions, including the expected price volatility. Changes in these assumptions can materially affect the fair value estimates. | |||
Fair Value Measurements [Policy Text Block] | ' | ||
l) | Fair Value Measurements | ||
The fair value hierarchy under GAAP is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following: | |||
Level 1 - | quoted prices (unadjusted) in active markets for identical assets or liabilities; | ||
Level 2 - | observable inputs other than Level I, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and | ||
Level 3 - | assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant to the fair value of the assets or liabilities. | ||
Derivative Liabilities [Policy Text Block] | ' | ||
m) | Derivative Liabilities | ||
The Company evaluates its financial instruments and other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815 Derivatives and Hedging. The result of this accounting treatment is that the fair value of the embedded derivative is marked- to-market at each balance sheet date and recorded as a liability and the change in fair value is recorded in the consolidated statements of operations as other income or expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. | |||
The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instruments that become subject to reclassification are reclassified at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not settlement of the derivative instrument is expected within 12 months of the balance sheet date. | |||
The Company uses the binomial option pricing model to value derivative liabilities. This model uses Level 3 inputs in the fair value hierarchy established by ASC 820 Fair Value Measurement. | |||
Recent Accounting Pronouncements [Policy Text Block] | ' | ||
n) | Recent Accounting Pronouncements | ||
There are no new accounting pronouncements that the Company recently adopted or are pending the Company’s adoption that are expected to have a material impact on the company’s results of operations, financial position or cash flows. |
Summary_of_Significant_Account2
Summary of Significant Accounting Policies (Tables) | 12 Months Ended | |||
Sep. 30, 2013 | ||||
Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block] | ' | |||
At September | ||||
At inception | 30, 2013 | |||
Risk-free interest rate | 0.28% | 0.10% | ||
Expected life (years) | 1.49 | 1.25 | ||
Expected volatility | 81.57% | 77.51% | ||
Stock price | $0.61 | $0.65 | ||
Dividend yields | 0.00% | 0.00% |
Equipment_Tables
Equipment (Tables) | 12 Months Ended | |||||||||||||||||||||
Sep. 30, 2013 | Sep. 30, 2012 | |||||||||||||||||||||
Schedule of Property, Plant and Equipment [Table Text Block] | ' | ' | ||||||||||||||||||||
30-Sep-13 | 30-Sep-12 | |||||||||||||||||||||
Accumulated | Accumulated | |||||||||||||||||||||
Cost | Depreciation | Net | Cost | Depreciation | Net | |||||||||||||||||
Computer equipment | $ | 5,631 | $ | 5,631 | $ | - | Computer equipment | $ | 5,631 | $ | 5,055 | $ | 576 |
Derivative_Liabilities_Tables
Derivative Liabilities (Tables) | 12 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Derivative Liabilities Activity [Table Text Block] | ' | |||||||
2013 | 2012 | |||||||
Balance, beginning of the period | $ | - | $ | 67,500 | ||||
Fair value at issuance of derivative liability | 919,000 | - | ||||||
Change in fair value of derivative liability | (15,000 | ) | (67,500 | ) | ||||
Balance, end of the period | $ | 904,000 | $ | - |
Promissory_Notes_Payable_Table
Promissory Notes Payable (Tables) | 12 Months Ended | ||||||||||||||||
Sep. 30, 2013 | |||||||||||||||||
Schedule of Debt [Table Text Block] | ' | ||||||||||||||||
September 30, | |||||||||||||||||
2013 | 2012 | ||||||||||||||||
Promissory note dated June 6, 2012 bearing interest at 8% per annum, due on demand | $ | - | $ | 49,000 | |||||||||||||
Promissory note dated June 26, 2012 bearing interest at 8% per annum, due on demand | - | 250,000 | |||||||||||||||
Promissory note dated December 31, 2012 bearing interest at 12% per annum, due on December 31, 2013 | 100,000 | - | |||||||||||||||
Promissory note dated January 9, 2013 with a principal balance of $84,060 (CDN$86,677), bearing interest at 12% per annum, secured by all the present and future assets of the Company; due on demand | 84,060 | - | |||||||||||||||
Promissory note dated January 9, 2013 with a principal balance of $26,803 (CDN$27,639), bearing interest at 12% per annum, secured by all the present and future assets of the Company; due on demand | 26,803 | - | |||||||||||||||
210,863 | 299,000 | ||||||||||||||||
Less: current portion | (210,863 | ) | (299,000 | ) | |||||||||||||
$ | - | $ | - | ||||||||||||||
Schedule of promissory note settlements [Table Text Block] | ' | ||||||||||||||||
Amount Settled | Units issued | ||||||||||||||||
Accrued | Loss on | ||||||||||||||||
Date of Note | Principal | Interest | Number | Fair Value | Settlement | ||||||||||||
Promissory notes payable | |||||||||||||||||
6-Jun-12 | 49,000 | 3,200 | 130,501 | 98,205 | 46,005 | ||||||||||||
26-Jun-12 | 250,000 | 15,233 | 663,082 | 498,972 | 233,739 | ||||||||||||
17-Oct-12 | 150,000 | 5,425 | 388,562 | 292,394 | 136,969 | ||||||||||||
14-Nov-12 | 50,000 | 1,501 | 128,753 | 96,887 | 45,386 | ||||||||||||
8-Feb-13 | 50,000 | 699 | 126,747 | 95,377 | 44,678 | ||||||||||||
549,000 | 26,058 | 1,437,645 | 1,081,835 | $ | 506,777 | ||||||||||||
Accounts payable | 1,108,506 | - | 2,771,265 | 2,085,386 | 976,880 | ||||||||||||
$ | 1,657,506 | $ | 26,058 | 4,208,910 | $ | 3,167,221 | $ | 1,483,657 | |||||||||
Schedule of fair value of warrants assumption [Table Text Block] | ' | ||||||||||||||||
Stock price | $0.61 | ||||||||||||||||
Exercise price | $0.75 | ||||||||||||||||
Expected volatility | 81.57% | ||||||||||||||||
Risk-free discount rate | 0.28% | ||||||||||||||||
Expected term | 1.49 years | ||||||||||||||||
Expected dividend yield | 0.00% |
Related_Party_Transactions_Tab
Related Party Transactions (Tables) | 12 Months Ended | ||||||||||
Sep. 30, 2013 | |||||||||||
Schedule of Related Party Transactions [Table Text Block] | ' | ||||||||||
23-Jan-04 | |||||||||||
Year ended September 30, | (Date of Inception) | ||||||||||
2013 | 2012 | to September 30, 2013 | |||||||||
Management fees | $ | - | $ | - | $ | 14,625 | |||||
Rent | - | - | 3,750 | ||||||||
Debt forgiven by directors | - | - | 33,666 | ||||||||
$ | - | $ | - | $ | 52,041 |
Commitments_Tables
Commitments (Tables) | 12 Months Ended | |||||||||||||||
Sep. 30, 2013 | ||||||||||||||||
Schedule of Stockholders' Equity Note, Warrants or Rights, Activity [Table Text Block] | ' | |||||||||||||||
Weighted | ||||||||||||||||
Average | ||||||||||||||||
Exercise | ||||||||||||||||
Number of Shares | Price | |||||||||||||||
Balance, September 30, 2011 | 2,655,479 | $ | 3.16 | |||||||||||||
Expired | (1,552,651 | ) | $ | 3.16 | ||||||||||||
Issued | 3,147,313 | $ | 0.93 | |||||||||||||
Balance, September 30, 2012 | 4,250,141 | $ | 1.16 | |||||||||||||
Expired | (1,549,628 | ) | $ | 2.56 | ||||||||||||
Issued | 6,448,966 | $ | 0.75 | |||||||||||||
Balance, September 30, 2013 | 9,149,479 | $ | 0.75 | |||||||||||||
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | ' | |||||||||||||||
Number | Exercise Price | Expiry Date | ||||||||||||||
2,700,513 | $ | 0.75 | 30-Nov-13 | |||||||||||||
6,448,966 | $ | 0.75 | 5-Jul-18 | |||||||||||||
9,149,479 | ||||||||||||||||
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | ' | |||||||||||||||
Weighted | Weighted | |||||||||||||||
Number of | Average | Average Grant | ||||||||||||||
Shares | Exercise Price | Date fair value | ||||||||||||||
Outstanding at September 30, 2011 | 2,375,000 | $ | 3.18 | |||||||||||||
Forfeited | (1,100,000 | ) | $ | 2.82 | ||||||||||||
Granted | 500,000 | $ | 1.5 | $ | 0.72 | |||||||||||
Outstanding at September 30, 2012 | 1,775,000 | $ | 2.94 | |||||||||||||
Expired | (550,000 | ) | $ | 3.86 | ||||||||||||
Forfeited | (150,000 | ) | $ | 3.72 | ||||||||||||
Granted | 2,000,000 | $ | 0.4 | $ | 0.5 | |||||||||||
Outstanding at September 30, 2013 | 3,075,000 | $ | 1.26 | |||||||||||||
Exercisable at September 30, 2013 | 2,305,000 | $ | 0.79 | |||||||||||||
Exercisable at September 30, 2012 | 905,000 | $ | 2.81 | |||||||||||||
Schedule of Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] | ' | |||||||||||||||
Number of Shares | Aggregate | Remaining | ||||||||||||||
Number | Exercise | Intrinsic | Contractual | |||||||||||||
Total | Vested | Price | Expiry Date | Value | Life (yrs) | |||||||||||
150,000 (1) | 150,000 | $ | 3.1 | 30-Jun-14 | - | 0.75 | ||||||||||
500,000 (2) | - | $ | 2.5 | 19-Oct-13 | - | 0.05 | ||||||||||
5,000 (3) | 5,000 | $ | 2.5 | 2-Mar-14 | - | 0.42 | ||||||||||
50,000 (4) | 50,000 | $ | 3.5 | 30-Jun-14 | - | 0.75 | ||||||||||
100,000 (5) | 100,000 | $ | 3.67 | 30-Mar-16 | - | 2.5 | ||||||||||
270,000 (6) | - | $ | 3 | 8-Feb-17 | - | 3.36 | ||||||||||
2,000,000 (7) | 2,000,000 | $ | 0.4 | 5-Jul-23 | 500,000 | 9.77 | ||||||||||
3,075,000 | 2,305,000 | 500,000 | ||||||||||||||
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | ' | |||||||||||||||
2013 | 2012 | |||||||||||||||
Risk-free interest rate | 2.73% | 0.83% - 2.19% | ||||||||||||||
Expected life of options | 10.0 years | 4.25 - 5.0 years | ||||||||||||||
Annualized volatility | 71.39% | 57.87% - 95.25% | ||||||||||||||
Dividend rate | 0.00% | 0.00% | ||||||||||||||
Schedule of Nonvested Share Activity [Table Text Block] | ' | |||||||||||||||
Weighted | Weighted | |||||||||||||||
Average | Average | |||||||||||||||
Number of | Exercise | Grant-Date | ||||||||||||||
Shares | Price | Fair Value | ||||||||||||||
Unvested options at September 30, 2011 | 1,445,000 | $ | 3.33 | $ | 2.17 | |||||||||||
Granted | 500,000 | $ | 1.5 | $ | 0.72 | |||||||||||
Forfeited | (900,000 | ) | $ | 2.74 | $ | 1.6 | ||||||||||
Vested | (175,000 | ) | $ | 3.71 | $ | 2.7 | ||||||||||
Unvested options at September 30, 2012 | 870,000 | $ | 2.81 | $ | 1.82 | |||||||||||
Granted | 2,000,000 | $ | 0.4 | $ | 0.5 | |||||||||||
Expired | (100,000 | ) | $ | 3.86 | $ | 2.49 | ||||||||||
Vested | (2,000,000 | ) | $ | 0.4 | $ | 0.5 | ||||||||||
Unvested options at September 30, 2013 | 770,000 | $ | 2.68 | $ | 1.74 | |||||||||||
Shares Issued For Services [Table Text Block] | ' | |||||||||||||||
2013 | 2012 | |||||||||||||||
Consulting fees | $ | - | $ | 312,903 | ||||||||||||
Research and development | - | 80,200 | ||||||||||||||
Salaries and wages | 1,002,500 | - | ||||||||||||||
$ | 1,002,500 | $ | 393,103 |
Income_Taxes_Tables
Income Taxes (Tables) | 12 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | ' | |||||||
2013 | 2012 | |||||||
Tax rate | 34% | 34% | ||||||
Net operating loss carryforwards | $ | 7,141,000 | $ | 6,775,000 | ||||
Research and development tax credits | 705,000 | 741,000 | ||||||
Foreign exchange | (19,000 | ) | 28,000 | |||||
Accrued bonuses | 34,000 | 34,000 | ||||||
Intangible asset costs | 51,000 | 34,000 | ||||||
Stock-based compensation | 633,000 | - | ||||||
Valuation allowance for deferred tax assets | (8,545,000 | ) | (7,612,000 | ) | ||||
Net deferred tax assets | $ | - | $ | - | ||||
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | ' | |||||||
2013 | 2012 | |||||||
Income benefit at statutory rate | $ | (1,258,000 | ) | $ | (2,823,000 | ) | ||
Foreign income taxed at foreign statutory rate | - | (2,000 | ) | |||||
Debt extinguishment | 501,000 | 1,302,000 | ||||||
Research and development tax credit | (17,000 | ) | (175,000 | ) | ||||
Fair value of derivative liability | 7,000 | (23,000 | ) | |||||
Debt accretion | - | 33,000 | ||||||
Other permanent differences | (5,000 | ) | 113,000 | |||||
Adjustment to prior years' tax provision | (161,000 | ) | - | |||||
Change in valuation allowance | 933,000 | 1,575,000 | ||||||
Income Tax Expense | $ | - | $ | - |
Business_Description_Basis_of_1
Business Description, Basis of Presentation and Liquidity (Narrative) (Details) (USD $) | 12 Months Ended |
Sep. 30, 2013 | |
M | |
Business Description, Basis Of Presentation And Liquidity 1 | $10,000,000 |
Business Description, Basis Of Presentation And Liquidity 2 | 12 |
Business Description, Basis Of Presentation And Liquidity 3 | 41,204,972 |
Business Description, Basis Of Presentation And Liquidity 4 | 37,504,926 |
Business Description, Basis Of Presentation And Liquidity 5 | 1,559,212 |
Business Description, Basis Of Presentation And Liquidity 6 | $6,000,000 |
Summary_of_Significant_Account3
Summary of Significant Accounting Policies (Narrative) (Details) | 12 Months Ended |
Sep. 30, 2013 | |
M | |
Summary Of Significant Accounting Policies 1 | 33.00% |
Summary Of Significant Accounting Policies 2 | 50.00% |
Summary Of Significant Accounting Policies 3 | 12,224,479 |
Summary Of Significant Accounting Policies 4 | 6,025,141 |
Summary Of Significant Accounting Policies 5 | 12 |
Derivative_Liabilities_Narrati
Derivative Liabilities (Narrative) (Details) | 12 Months Ended |
Sep. 30, 2013 | |
Derivative Liabilities 1 | 6,448,966 |
Promissory_Notes_Payable_Narra
Promissory Notes Payable (Narrative) (Details) | 12 Months Ended | |
Sep. 30, 2013 | Sep. 30, 2013 | |
USD ($) | CAD | |
D | ||
Promissory Notes Payable 1 | $49,000 | ' |
Promissory Notes Payable 2 | 8.00% | 8.00% |
Promissory Notes Payable 3 | 3,200 | ' |
Promissory Notes Payable 4 | 130,501 | 130,501 |
Promissory Notes Payable 5 | $0.75 | ' |
Promissory Notes Payable 6 | 4,900 | ' |
Promissory Notes Payable 7 | 0 | ' |
Promissory Notes Payable 8 | 1,215 | ' |
Promissory Notes Payable 9 | 250,000 | ' |
Promissory Notes Payable 10 | 8.00% | 8.00% |
Promissory Notes Payable 11 | 15,233 | ' |
Promissory Notes Payable 12 | 663,082 | 663,082 |
Promissory Notes Payable 13 | $0.75 | ' |
Promissory Notes Payable 14 | 150,000 | ' |
Promissory Notes Payable 15 | 8.00% | 8.00% |
Promissory Notes Payable 16 | 5,425 | ' |
Promissory Notes Payable 17 | 388,562 | 388,562 |
Promissory Notes Payable 18 | $0.75 | ' |
Promissory Notes Payable 19 | 50,000 | ' |
Promissory Notes Payable 20 | 8.00% | 8.00% |
Promissory Notes Payable 21 | 1,501 | ' |
Promissory Notes Payable 22 | 128,753 | 128,753 |
Promissory Notes Payable 23 | $0.75 | ' |
Promissory Notes Payable 24 | 100,000 | ' |
Promissory Notes Payable 25 | 12.00% | 12.00% |
Promissory Notes Payable 26 | 50,000 | ' |
Promissory Notes Payable 27 | 10.00% | 10.00% |
Promissory Notes Payable 28 | 699 | ' |
Promissory Notes Payable 29 | 126,747 | 126,747 |
Promissory Notes Payable 30 | $0.75 | ' |
Promissory Notes Payable 31 | 87,865 | ' |
Promissory Notes Payable 32 | ' | 86,677 |
Promissory Notes Payable 33 | 12.00% | 12.00% |
Promissory Notes Payable 34 | 28,017 | ' |
Promissory Notes Payable 35 | ' | 27,639 |
Promissory Notes Payable 36 | 12.00% | 12.00% |
Promissory Notes Payable 37 | 10 | 10 |
Promissory Notes Payable 38 | 100 | ' |
Promissory Notes Payable 39 | 500 | ' |
Promissory Notes Payable 40 | 0.75 | ' |
Promissory Notes Payable 41 | 0.753 | ' |
Promissory Notes Payable 42 | 0.61 | ' |
Promissory Notes Payable 43 | 0.143 | ' |
Promissory Notes Payable 44 | $11,449 | ' |
Capital_Stock_Narrative_Detail
Capital Stock (Narrative) (Details) (USD $) | 12 Months Ended |
Sep. 30, 2013 | |
Y | |
Capital Stock 1 | 25,000,000 |
Capital Stock 2 | 150,000,000 |
Capital Stock 3 | 222,222 |
Capital Stock 4 | $3.60 |
Capital Stock 5 | $800,000 |
Capital Stock 6 | 333,000 |
Capital Stock 7 | 92,500 |
Capital Stock 8 | $3.60 |
Capital Stock 9 | 150,000 |
Capital Stock 10 | $3.50 |
Capital Stock 11 | 525,000 |
Capital Stock 12 | $5 |
Capital Stock 13 | 10,000 |
Capital Stock 14 | $4.50 |
Capital Stock 15 | 45,000 |
Capital Stock 16 | 50,000 |
Capital Stock 17 | $3.86 |
Capital Stock 18 | 193,000 |
Capital Stock 19 | 65,000 |
Capital Stock 20 | 65,000 |
Capital Stock 21 | $5.24 |
Capital Stock 22 | 340,600 |
Capital Stock 23 | 25,000 |
Capital Stock 24 | $5.07 |
Capital Stock 25 | 126,750 |
Capital Stock 26 | 142,698 |
Capital Stock 27 | $4.25 |
Capital Stock 28 | 606,467 |
Capital Stock 29 | $5 |
Capital Stock 30 | 25,000 |
Capital Stock 31 | $2.63 |
Capital Stock 32 | 65,750 |
Capital Stock 33 | 25,000 |
Capital Stock 34 | $2.50 |
Capital Stock 35 | 62,500 |
Capital Stock 36 | 89,148 |
Capital Stock 37 | $2.25 |
Capital Stock 38 | 200,583 |
Capital Stock 39 | $4 |
Capital Stock 40 | 10,800 |
Capital Stock 41 | $2.25 |
Capital Stock 42 | 24,300 |
Capital Stock 43 | $4 |
Capital Stock 44 | 2,500 |
Capital Stock 45 | $2 |
Capital Stock 46 | 5,000 |
Capital Stock 47 | 75,000 |
Capital Stock 48 | 36,000 |
Capital Stock 49 | $2.25 |
Capital Stock 50 | 81,000 |
Capital Stock 51 | $4 |
Capital Stock 52 | 8,100 |
Capital Stock 53 | 29,227 |
Capital Stock 54 | $2.25 |
Capital Stock 55 | 495,556 |
Capital Stock 56 | $2.25 |
Capital Stock 57 | 1,115,000 |
Capital Stock 58 | $2.25 |
Capital Stock 59 | 22,222 |
Capital Stock 60 | $2.51 |
Capital Stock 61 | 500,000 |
Capital Stock 62 | 128,888 |
Capital Stock 63 | $2.25 |
Capital Stock 64 | 289,998 |
Capital Stock 65 | 40,000 |
Capital Stock 66 | $4 |
Capital Stock 67 | 88,888 |
Capital Stock 68 | $2.25 |
Capital Stock 69 | 19,000 |
Capital Stock 70 | 266,666 |
Capital Stock 71 | $2.25 |
Capital Stock 72 | 600,000 |
Capital Stock 73 | $2.25 |
Capital Stock 74 | 300,000 |
Capital Stock 75 | 49,505 |
Capital Stock 76 | $2.02 |
Capital Stock 77 | 92,499 |
Capital Stock 78 | $2.60 |
Capital Stock 79 | 240,498 |
Capital Stock 80 | $3.50 |
Capital Stock 81 | 9,825 |
Capital Stock 82 | $2.85 |
Capital Stock 83 | 941,000 |
Capital Stock 84 | $2.50 |
Capital Stock 85 | 2,352,500 |
Capital Stock 86 | $3.50 |
Capital Stock 87 | 400,000 |
Capital Stock 88 | 1,000,000 |
Capital Stock 89 | 3.5 |
Capital Stock 90 | 1,444,000 |
Capital Stock 91 | 444,000 |
Capital Stock 92 | 3.5 |
Capital Stock 93 | 3.15 |
Capital Stock 94 | 68.45% |
Capital Stock 95 | 1.5 |
Capital Stock 96 | 0.00% |
Capital Stock 97 | 163,000 |
Capital Stock 98 | $2.75 |
Capital Stock 99 | 448,250 |
Capital Stock 100 | $3.75 |
Capital Stock 101 | 9,000 |
Capital Stock 102 | $2.75 |
Capital Stock 103 | $3.75 |
Capital Stock 104 | 510,638 |
Capital Stock 105 | $2.35 |
Capital Stock 106 | 82,310 |
Capital Stock 107 | $2.25 |
Capital Stock 108 | $3.50 |
Capital Stock 109 | 245,748 |
Capital Stock 110 | $2.25 |
Capital Stock 111 | $3 |
Capital Stock 112 | 393,846 |
Capital Stock 113 | $2.75 |
Capital Stock 114 | 1,083,075 |
Capital Stock 115 | $4.50 |
Capital Stock 116 | 65,363 |
Capital Stock 117 | 3,636 |
Capital Stock 118 | $2.75 |
Capital Stock 119 | $4.50 |
Capital Stock 120 | 853,075 |
Capital Stock 121 | 2.5 |
Capital Stock 122 | 504,160 |
Capital Stock 123 | $3 |
Capital Stock 124 | 3 |
Capital Stock 125 | 4.12 |
Capital Stock 126 | 78.33% |
Capital Stock 127 | 2 |
Capital Stock 128 | 0.00% |
Capital Stock 129 | 0.52% |
Capital Stock 130 | 145,063 |
Capital Stock 131 | $4.12 |
Capital Stock 132 | 398,922 |
Capital Stock 133 | 26,032 |
Capital Stock 134 | 198,738 |
Capital Stock 135 | 181,818 |
Capital Stock 136 | $4.12 |
Capital Stock 137 | 500,000 |
Capital Stock 138 | 249,090 |
Capital Stock 139 | 29,851 |
Capital Stock 140 | $3.35 |
Capital Stock 141 | 100,000 |
Capital Stock 142 | $4.50 |
Capital Stock 143 | 2,985 |
Capital Stock 144 | $3.35 |
Capital Stock 145 | $4.50 |
Capital Stock 146 | 61,014 |
Capital Stock 147 | $3.75 |
Capital Stock 148 | 228,800 |
Capital Stock 149 | $5.25 |
Capital Stock 150 | 33,334 |
Capital Stock 151 | $3 |
Capital Stock 152 | 100,000 |
Capital Stock 153 | $4 |
Capital Stock 154 | 700,000 |
Capital Stock 155 | $2.25 |
Capital Stock 156 | 1,575,000 |
Capital Stock 157 | 650,000 |
Capital Stock 158 | 975,000 |
Capital Stock 159 | $2 |
Capital Stock 160 | 84,963 |
Capital Stock 161 | 975,000 |
Capital Stock 162 | 84,963 |
Capital Stock 163 | 2 |
Capital Stock 164 | 1.5 |
Capital Stock 165 | 69.00% |
Capital Stock 166 | 1 |
Capital Stock 167 | 0.00% |
Capital Stock 168 | 0.10% |
Capital Stock 169 | 615,600 |
Capital Stock 170 | $1.25 |
Capital Stock 171 | 769,500 |
Capital Stock 172 | $2 |
Capital Stock 173 | 77,000 |
Capital Stock 174 | 8,000 |
Capital Stock 175 | $2 |
Capital Stock 176 | 15,896 |
Capital Stock 177 | 15,896 |
Capital Stock 178 | 2 |
Capital Stock 179 | 1.74 |
Capital Stock 180 | 84.88% |
Capital Stock 181 | 1 |
Capital Stock 182 | 0.15% |
Capital Stock 183 | 0.00% |
Capital Stock 184 | 270,000 |
Capital Stock 185 | $1.25 |
Capital Stock 186 | 337,500 |
Capital Stock 187 | $2 |
Capital Stock 188 | 33,750 |
Capital Stock 189 | 2,700,513 |
Capital Stock 190 | 1,297,889 |
Capital Stock 191 | 52,367 |
Capital Stock 192 | $0.75 |
Capital Stock 193 | 75,000 |
Capital Stock 194 | 4,208,910 |
Capital Stock 195 | 549,000 |
Capital Stock 196 | 26,058 |
Capital Stock 197 | 1,108,506 |
Capital Stock 198 | $0.75 |
Capital Stock 199 | 2,196,133 |
Capital Stock 200 | $0.40 |
Capital Stock 201 | 878,453 |
Capital Stock 202 | $0.75 |
Capital Stock 203 | 89,680 |
Capital Stock 204 | 43,923 |
Capital Stock 205 | $0.75 |
Capital Stock 206 | 16,494 |
Capital Stock 207 | 6,448,966 |
Capital Stock 208 | $0.00 |
Capital Stock 209 | 1.5 |
Capital Stock 210 | $60,000 |
Capital Stock 211 | 120,000 |
Capital Stock 212 | $0.50 |
Capital Stock 213 | $1 |
Equity_Line_of_Credit_Narrativ
Equity Line of Credit (Narrative) (Details) (USD $) | 12 Months Ended |
Sep. 30, 2013 | |
M | |
Equity Line Of Credit 1 | $10,000,000 |
Equity Line Of Credit 2 | 10,000,000 |
Equity Line Of Credit 3 | 36 |
Equity Line Of Credit 4 | $0.50 |
Equity Line Of Credit 5 | 250,000 |
Equity Line Of Credit 6 | 100,000 |
Equity Line Of Credit 7 | 341,858 |
Equity Line Of Credit 8 | 133,409 |
Equity Line Of Credit 9 | 10,000,000 |
Equity Line Of Credit 10 | $71,335 |
Related_Party_Transactions_Nar
Related Party Transactions (Narrative) (Details) (USD $) | 12 Months Ended |
Sep. 30, 2013 | |
Related Party Transactions 1 | $81,072 |
Related Party Transactions 2 | 479,434 |
Related Party Transactions 3 | 30,447 |
Related Party Transactions 4 | 127,452 |
Related Party Transactions 5 | 2,000,000 |
Related Party Transactions 6 | $0.40 |
Related Party Transactions 7 | 1,002,500 |
Related Party Transactions 8 | 0 |
Related Party Transactions 9 | 4,000,000 |
Related Party Transactions 10 | 25.00% |
Related Party Transactions 11 | 25.00% |
Related Party Transactions 12 | 25.00% |
Related Party Transactions 13 | $5,000,000 |
Related Party Transactions 14 | 25.00% |
Commitments_Narrative_Details
Commitments (Narrative) (Details) (USD $) | 12 Months Ended |
Sep. 30, 2013 | |
Y | |
Commitments 1 | 9,149,479 |
Commitments 2 | 200,000 |
Commitments 3 | $3.50 |
Commitments 4 | 1.5 |
Commitments 5 | 80,200 |
Commitments 6 | 0.11% |
Commitments 7 | 1 |
Commitments 8 | 79.46% |
Commitments 9 | 0.00% |
Commitments 10 | 3,000,000 |
Commitments 11 | 10.00% |
Commitments 12 | 4 |
Commitments 13 | 25.00% |
Commitments 14 | 1 |
Commitments 15 | 10.00% |
Commitments 16 | 110.00% |
Commitments 17 | 4,000,000 |
Commitments 18 | 18,600 |
Commitments 19 | 0.31% |
Commitments 20 | 2 |
Commitments 21 | 84.74% |
Commitments 22 | 0.00% |
Commitments 23 | 18,600 |
Commitments 24 | 100,000 |
Commitments 25 | 740,000 |
Commitments 26 | 0 |
Commitments 27 | 0 |
Commitments 28 | 267,000 |
Commitments 29 | 6,500 |
Commitments 30 | 90,000 |
Commitments 31 | 90,000 |
Commitments 32 | 90,000 |
Commitments 33 | 1,002,500 |
Commitments 34 | 0 |
Commitments 35 | 150,000 |
Commitments 36 | 0 |
Commitments 37 | 163,415 |
Commitments 38 | 1,100,000 |
Commitments 39 | 33,493 |
Commitments 40 | $0 |
Income_Taxes_Narrative_Details
Income Taxes (Narrative) (Details) (USD $) | 12 Months Ended |
Sep. 30, 2013 | |
Income Taxes 1 | $21,022,000 |
Income Taxes 2 | $20,196,000 |
Supplemental_Cash_Flow_Informa1
Supplemental Cash Flow Information (Narrative) (Details) | 12 Months Ended | |
Sep. 30, 2013 | Sep. 30, 2013 | |
USD ($) | CAD | |
Supplemental Cash Flow Information 1 | $100,000 | ' |
Supplemental Cash Flow Information 2 | 87,865 | ' |
Supplemental Cash Flow Information 3 | ' | 86,677 |
Supplemental Cash Flow Information 4 | 28,017 | ' |
Supplemental Cash Flow Information 5 | ' | 27,639 |
Supplemental Cash Flow Information 6 | 4,208,910 | 4,208,910 |
Supplemental Cash Flow Information 7 | $1.02 | ' |
Supplemental Cash Flow Information 8 | 549,000 | ' |
Supplemental Cash Flow Information 9 | 26,058 | ' |
Supplemental Cash Flow Information 10 | 1,108,506 | ' |
Supplemental Cash Flow Information 11 | $0.75 | ' |
Supplemental Cash Flow Information 12 | 11,449 | ' |
Supplemental Cash Flow Information 13 | 1,472,208 | ' |
Supplemental Cash Flow Information 14 | 544,667 | 544,667 |
Supplemental Cash Flow Information 15 | $1.92 | ' |
Supplemental Cash Flow Information 16 | 272,333 | ' |
Supplemental Cash Flow Information 17 | 22,333 | ' |
Supplemental Cash Flow Information 18 | 2,155,846 | 2,155,846 |
Supplemental Cash Flow Information 19 | $1.92 | ' |
Supplemental Cash Flow Information 20 | 1,077,923 | ' |
Supplemental Cash Flow Information 21 | 30,034 | ' |
Supplemental Cash Flow Information 22 | $0.75 | ' |
Supplemental Cash Flow Information 23 | 3,829,333 | ' |
Supplemental Cash Flow Information 24 | 75,000 | 75,000 |
Supplemental Cash Flow Information 25 | $1 | ' |
Supplemental Cash Flow Information 26 | $75,000 | ' |
Fair_Value_Liabilities_Measure
Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis (Details) (USD $) | 12 Months Ended |
Sep. 30, 2013 | |
Summary Of Significant Accounting Policies Fair Value, Liabilities Measured On Recurring And Nonrecurring Basis 1 | 0.28% |
Summary Of Significant Accounting Policies Fair Value, Liabilities Measured On Recurring And Nonrecurring Basis 2 | 0.10% |
Summary Of Significant Accounting Policies Fair Value, Liabilities Measured On Recurring And Nonrecurring Basis 3 | 1.49 |
Summary Of Significant Accounting Policies Fair Value, Liabilities Measured On Recurring And Nonrecurring Basis 4 | 1.25 |
Summary Of Significant Accounting Policies Fair Value, Liabilities Measured On Recurring And Nonrecurring Basis 5 | 81.57% |
Summary Of Significant Accounting Policies Fair Value, Liabilities Measured On Recurring And Nonrecurring Basis 6 | 77.51% |
Summary Of Significant Accounting Policies Fair Value, Liabilities Measured On Recurring And Nonrecurring Basis 7 | $0.61 |
Summary Of Significant Accounting Policies Fair Value, Liabilities Measured On Recurring And Nonrecurring Basis 8 | $0.65 |
Summary Of Significant Accounting Policies Fair Value, Liabilities Measured On Recurring And Nonrecurring Basis 9 | 0.00% |
Summary Of Significant Accounting Policies Fair Value, Liabilities Measured On Recurring And Nonrecurring Basis 10 | 0.00% |
Schedule_of_Property_Plant_and
Schedule of Property, Plant and Equipment (Details) (USD $) | 12 Months Ended | |
Sep. 30, 2013 | Sep. 30, 2012 | |
Equipment Schedule Of Property, Plant And Equipment 1 | $5,631 | ' |
Equipment Schedule Of Property, Plant And Equipment 2 | 5,631 | ' |
Equipment Schedule Of Property, Plant And Equipment 3 | 0 | ' |
Equipment Schedule Of Property, Plant And Equipment 1 | ' | 5,631 |
Equipment Schedule Of Property, Plant And Equipment 2 | ' | 5,055 |
Equipment Schedule Of Property, Plant And Equipment 3 | ' | $576 |
Derivative_Liabilities_Activit
Derivative Liabilities Activity (Details) (USD $) | 12 Months Ended |
Sep. 30, 2013 | |
Derivative Liabilities Derivative Liabilities Activity 1 | $0 |
Derivative Liabilities Derivative Liabilities Activity 2 | 67,500 |
Derivative Liabilities Derivative Liabilities Activity 3 | 919,000 |
Derivative Liabilities Derivative Liabilities Activity 4 | 0 |
Derivative Liabilities Derivative Liabilities Activity 5 | -15,000 |
Derivative Liabilities Derivative Liabilities Activity 6 | -67,500 |
Derivative Liabilities Derivative Liabilities Activity 7 | 904,000 |
Derivative Liabilities Derivative Liabilities Activity 8 | $0 |
Schedule_of_Debt_Details
Schedule of Debt (Details) | 12 Months Ended | |
Sep. 30, 2013 | Sep. 30, 2013 | |
USD ($) | CAD | |
Promissory Notes Payable Schedule Of Debt 1 | 8.00% | 8.00% |
Promissory Notes Payable Schedule Of Debt 2 | $0 | ' |
Promissory Notes Payable Schedule Of Debt 3 | 49,000 | ' |
Promissory Notes Payable Schedule Of Debt 4 | 8.00% | 8.00% |
Promissory Notes Payable Schedule Of Debt 5 | 0 | ' |
Promissory Notes Payable Schedule Of Debt 6 | 250,000 | ' |
Promissory Notes Payable Schedule Of Debt 7 | 12.00% | 12.00% |
Promissory Notes Payable Schedule Of Debt 8 | 100,000 | ' |
Promissory Notes Payable Schedule Of Debt 9 | 0 | ' |
Promissory Notes Payable Schedule Of Debt 10 | 84,060 | ' |
Promissory Notes Payable Schedule Of Debt 11 | ' | 86,677 |
Promissory Notes Payable Schedule Of Debt 12 | 12.00% | 12.00% |
Promissory Notes Payable Schedule Of Debt 13 | 84,060 | ' |
Promissory Notes Payable Schedule Of Debt 14 | 0 | ' |
Promissory Notes Payable Schedule Of Debt 15 | 26,803 | ' |
Promissory Notes Payable Schedule Of Debt 16 | ' | 27,639 |
Promissory Notes Payable Schedule Of Debt 17 | 12.00% | 12.00% |
Promissory Notes Payable Schedule Of Debt 18 | 26,803 | ' |
Promissory Notes Payable Schedule Of Debt 19 | 0 | ' |
Promissory Notes Payable Schedule Of Debt 20 | 210,863 | ' |
Promissory Notes Payable Schedule Of Debt 21 | 299,000 | ' |
Promissory Notes Payable Schedule Of Debt 22 | -210,863 | ' |
Promissory Notes Payable Schedule Of Debt 23 | -299,000 | ' |
Promissory Notes Payable Schedule Of Debt 24 | 0 | ' |
Promissory Notes Payable Schedule Of Debt 25 | $0 | ' |
Schedule_of_promissory_note_se
Schedule of promissory note settlements (Details) (USD $) | 12 Months Ended |
Sep. 30, 2013 | |
Promissory Notes Payable Schedule Of Promissory Note Settlements 1 | $49,000 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 2 | 3,200 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 3 | 130,501 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 4 | 98,205 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 5 | 46,005 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 6 | 250,000 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 7 | 15,233 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 8 | 663,082 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 9 | 498,972 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 10 | 233,739 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 11 | 150,000 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 12 | 5,425 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 13 | 388,562 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 14 | 292,394 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 15 | 136,969 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 16 | 50,000 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 17 | 1,501 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 18 | 128,753 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 19 | 96,887 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 20 | 45,386 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 21 | 50,000 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 22 | 699 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 23 | 126,747 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 24 | 95,377 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 25 | 44,678 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 26 | 549,000 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 27 | 26,058 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 28 | 1,437,645 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 29 | 1,081,835 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 30 | 506,777 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 31 | 1,108,506 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 32 | 0 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 33 | 2,771,265 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 34 | 2,085,386 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 35 | 976,880 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 36 | 1,657,506 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 37 | 26,058 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 38 | 4,208,910 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 39 | 3,167,221 |
Promissory Notes Payable Schedule Of Promissory Note Settlements 40 | $1,483,657 |
Schedule_of_fair_value_of_warr
Schedule of fair value of warrants assumption (Details) (USD $) | 12 Months Ended |
Sep. 30, 2013 | |
Y | |
Promissory Notes Payable Schedule Of Fair Value Of Warrants Assumption 1 | $0.61 |
Promissory Notes Payable Schedule Of Fair Value Of Warrants Assumption 2 | $0.75 |
Promissory Notes Payable Schedule Of Fair Value Of Warrants Assumption 3 | 81.57% |
Promissory Notes Payable Schedule Of Fair Value Of Warrants Assumption 4 | 0.28% |
Promissory Notes Payable Schedule Of Fair Value Of Warrants Assumption 5 | 1.49 |
Promissory Notes Payable Schedule Of Fair Value Of Warrants Assumption 6 | 0.00% |
Schedule_of_Related_Party_Tran
Schedule of Related Party Transactions (Details) (USD $) | 12 Months Ended |
Sep. 30, 2013 | |
Related Party Transactions Schedule Of Related Party Transactions 1 | $0 |
Related Party Transactions Schedule Of Related Party Transactions 2 | 0 |
Related Party Transactions Schedule Of Related Party Transactions 3 | 14,625 |
Related Party Transactions Schedule Of Related Party Transactions 4 | 0 |
Related Party Transactions Schedule Of Related Party Transactions 5 | 0 |
Related Party Transactions Schedule Of Related Party Transactions 6 | 3,750 |
Related Party Transactions Schedule Of Related Party Transactions 7 | 0 |
Related Party Transactions Schedule Of Related Party Transactions 8 | 0 |
Related Party Transactions Schedule Of Related Party Transactions 9 | 33,666 |
Related Party Transactions Schedule Of Related Party Transactions 10 | 0 |
Related Party Transactions Schedule Of Related Party Transactions 11 | 0 |
Related Party Transactions Schedule Of Related Party Transactions 12 | $52,041 |
Schedule_of_Stockholders_Equit
Schedule of Stockholders' Equity Note, Warrants or Rights, Activity (Details) (USD $) | 12 Months Ended |
Sep. 30, 2013 | |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 1 | $2,655,479 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 2 | 3.16 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 3 | -1,552,651 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 4 | 3.16 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 5 | 3,147,313 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 6 | 0.93 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 7 | 4,250,141 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 8 | 1.16 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 9 | -1,549,628 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 10 | 2.56 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 11 | 6,448,966 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 12 | 0.75 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 13 | $9,149,479 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 14 | 0.75 |
Schedule_of_Stockholders_Equit1
Schedule of Stockholders' Equity Note, Warrants or Rights (Details) (USD $) | 12 Months Ended |
Sep. 30, 2013 | |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights 1 | $2,700,513 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights 2 | 0.75 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights 3 | 6,448,966 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights 4 | 0.75 |
Commitments Schedule Of Stockholders' Equity Note, Warrants Or Rights 5 | $9,149,479 |
Schedule_of_Sharebased_Compens
Schedule of Share-based Compensation, Stock Options, Activity (Details) (USD $) | 12 Months Ended |
Sep. 30, 2013 | |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 1 | $2,375,000 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 2 | 3.18 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 3 | -1,100,000 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 4 | 2.82 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 5 | 500,000 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 6 | 1.5 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 7 | 0.72 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 8 | 1,775,000 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 9 | 2.94 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 10 | -550,000 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 11 | 3.86 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 12 | -150,000 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 13 | 3.72 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 14 | 2,000,000 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 15 | 0.4 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 16 | 0.5 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 17 | 3,075,000 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 18 | 1.26 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 19 | 2,305,000 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 20 | 0.79 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 21 | $905,000 |
Commitments Schedule Of Share-based Compensation, Stock Options, Activity 22 | 2.81 |
Schedule_of_Disclosure_of_Shar
Schedule of Disclosure of Share-based Compensation Arrangements by Share-based Payment Award (Details) (USD $) | 12 Months Ended |
Sep. 30, 2013 | |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 1 | $150,000 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 2 | 150,000 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 3 | 3.1 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 4 | 0 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 5 | 0.75 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 6 | 500,000 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 7 | 0 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 8 | 2.5 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 9 | 0 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 10 | 0.05 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 11 | 5,000 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 12 | 5,000 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 13 | 2.5 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 14 | 0 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 15 | 0.42 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 16 | 50,000 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 17 | 50,000 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 18 | 3.5 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 19 | 0 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 20 | 0.75 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 21 | 100,000 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 22 | 100,000 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 23 | 3.67 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 24 | 0 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 25 | 2.5 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 26 | 270,000 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 27 | 0 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 28 | 3 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 29 | 0 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 30 | 3.36 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 31 | 2,000,000 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 32 | 2,000,000 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 33 | 0.4 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 34 | 500,000 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 35 | 9.77 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 36 | 3,075,000 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 37 | 2,305,000 |
Commitments Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 38 | $500,000 |
Schedule_of_Sharebased_Payment
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) | 12 Months Ended |
Sep. 30, 2013 | |
Y | |
Commitments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 1 | 2.73% |
Commitments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 2 | 0.83% |
Commitments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 3 | 2.19% |
Commitments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 4 | 10 |
Commitments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 5 | 4.25 |
Commitments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 6 | 5 |
Commitments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 7 | 71.39% |
Commitments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 8 | 57.87% |
Commitments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 9 | 95.25% |
Commitments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 10 | 0.00% |
Commitments Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 11 | 0.00% |
Schedule_of_Nonvested_Share_Ac
Schedule of Nonvested Share Activity (Details) (USD $) | 12 Months Ended |
Sep. 30, 2013 | |
Commitments Schedule Of Nonvested Share Activity 1 | $1,445,000 |
Commitments Schedule Of Nonvested Share Activity 2 | 3.33 |
Commitments Schedule Of Nonvested Share Activity 3 | 2.17 |
Commitments Schedule Of Nonvested Share Activity 4 | 500,000 |
Commitments Schedule Of Nonvested Share Activity 5 | 1.5 |
Commitments Schedule Of Nonvested Share Activity 6 | 0.72 |
Commitments Schedule Of Nonvested Share Activity 7 | -900,000 |
Commitments Schedule Of Nonvested Share Activity 8 | 2.74 |
Commitments Schedule Of Nonvested Share Activity 9 | 1.6 |
Commitments Schedule Of Nonvested Share Activity 10 | -175,000 |
Commitments Schedule Of Nonvested Share Activity 11 | 3.71 |
Commitments Schedule Of Nonvested Share Activity 12 | 2.7 |
Commitments Schedule Of Nonvested Share Activity 13 | 870,000 |
Commitments Schedule Of Nonvested Share Activity 14 | 2.81 |
Commitments Schedule Of Nonvested Share Activity 15 | 1.82 |
Commitments Schedule Of Nonvested Share Activity 16 | 2,000,000 |
Commitments Schedule Of Nonvested Share Activity 17 | 0.4 |
Commitments Schedule Of Nonvested Share Activity 18 | 0.5 |
Commitments Schedule Of Nonvested Share Activity 19 | -100,000 |
Commitments Schedule Of Nonvested Share Activity 20 | 3.86 |
Commitments Schedule Of Nonvested Share Activity 21 | 2.49 |
Commitments Schedule Of Nonvested Share Activity 22 | -2,000,000 |
Commitments Schedule Of Nonvested Share Activity 23 | 0.4 |
Commitments Schedule Of Nonvested Share Activity 24 | 0.5 |
Commitments Schedule Of Nonvested Share Activity 25 | $770,000 |
Commitments Schedule Of Nonvested Share Activity 26 | 2.68 |
Commitments Schedule Of Nonvested Share Activity 27 | 1.74 |
Shares_Issued_For_Services_Det
Shares Issued For Services (Details) (USD $) | 12 Months Ended |
Sep. 30, 2013 | |
Commitments Shares Issued For Services 1 | $0 |
Commitments Shares Issued For Services 2 | 312,903 |
Commitments Shares Issued For Services 3 | 0 |
Commitments Shares Issued For Services 4 | 80,200 |
Commitments Shares Issued For Services 5 | 1,002,500 |
Commitments Shares Issued For Services 6 | 0 |
Commitments Shares Issued For Services 7 | 1,002,500 |
Commitments Shares Issued For Services 8 | $393,103 |
Schedule_of_Deferred_Tax_Asset
Schedule of Deferred Tax Assets and Liabilities (Details) (USD $) | 12 Months Ended |
Sep. 30, 2013 | |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 1 | 34.00% |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 2 | 34.00% |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 3 | $7,141,000 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 4 | 6,775,000 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 5 | 705,000 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 6 | 741,000 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 7 | -19,000 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 8 | 28,000 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 9 | 34,000 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 10 | 34,000 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 11 | 51,000 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 12 | 34,000 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 13 | 633,000 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 14 | 0 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 15 | -8,545,000 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 16 | -7,612,000 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 17 | 0 |
Income Taxes Schedule Of Deferred Tax Assets And Liabilities 18 | $0 |
Schedule_of_Effective_Income_T
Schedule of Effective Income Tax Rate Reconciliation (Details) (USD $) | 12 Months Ended |
Sep. 30, 2013 | |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 1 | ($1,258,000) |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 2 | -2,823,000 |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 3 | 0 |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 4 | -2,000 |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 5 | 501,000 |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 6 | 1,302,000 |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 7 | -17,000 |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 8 | -175,000 |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 9 | 7,000 |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 10 | -23,000 |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 11 | 0 |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 12 | 33,000 |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 13 | -5,000 |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 14 | 113,000 |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 15 | -161,000 |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 16 | 0 |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 17 | 933,000 |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 18 | 1,575,000 |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 19 | 0 |
Income Taxes Schedule Of Effective Income Tax Rate Reconciliation 20 | $0 |